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The proliferation of new psychoactive substances, or
‘legal highs’, has caused moral panic in recent years.
But it has also thrown the existing regulatory measures
for drugs into sharp relief. As quickly as policy makers
to seek to control new substances through the Misuse
of Drugs Act, others are being manufactured and put
on the market. The effects of these new substances are
unknown and untested and it is this uncertainty
combined with easy accessibility that presents major
challenges to public safety.
However, these challenges also provide an
opportunity to look again at drug control policy
without a rerun of redundant debates about whether
to be ‘tough’ or ‘soft’ on drugs. Instead, this pamphlet
adopts a systems approach and considers drug policy
as a ‘wicked issue’ to which there is no solution, and no
ultimate winners or losers. Fundamentally, it seeks an
improvement to policy that will be supported by
people who otherwise disagree about what the goals
of policy are.
It is 40 years since the Misuse of Drugs Act
became law and the ‘drug problem’ is no nearer being
solved. Taking Drugs Seriously argues that it is time for
a new approach to policy making, legislation and
debate on drugs issues, focusing on developing
consensus while building better evidence about what
works.
Jonathan Birdwell is a Researcher at Demos. Jake
Chapman is an Associate of Demos. Nicola Singleton is
Director of Policy and Research at the UK Drug Policy
Commission.
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Foreword
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The debate about drug control is a long-standing one and shows
little sign of receding. The Misuse of Drugs Act is now 40 years
old and the calls for its review are becoming more frequent,
particularly in the light of the number of new synthetic drugs
which are being produced and sold, especially via the internet.
The UK Drug Policy Commission (UKDPC) has, over the
past four years, sought to foster a more informed and evidence-
based approach to drug policy. But the challenge for society and
policy makers faced with these new ‘legal highs’ is the paucity of
robust evidence upon which to make objective decisions. There
is then a risk that making a hasty decision about controlling a
new drug may, on occasions, make matters worse and increase
harms, both to individuals and wider society.
Unfortunately, the debate about drug policy often degener-
ates into a polarised one, where any pragmatic suggestions for
change and improvement will be decried by those on opposing
sides of the debate. It was against this background that the
UKDPC was genuinely keen to explore with Demos whether and
how we might approach this challenge in a fresh way. We are
grateful to the AB Charitable Trust for their support to enable us
to do this.
Keeping pace with rapid technological developments is
challenging to legislators and those responsible for enforcing the
law, as the experience from other countries also shows. The con-
clusions we reach will, we hope, help people to begin to think
differently about how society might set about controlling harmful
substances, enhance understanding about the legislative options
available and stimulate more productive discussion about the
steps that could be taken to tackle these issues in this country.
Dame Ruth Runciman
Chair, UK Drug Policy Commission
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The emergence of mephedrone triggered a growing disquiet in
the UK about ‘legal highs’: new psychoactive substances that
have been manufactured and are made widely available in an
uncontrolled and unregulated way to purchase in outlets and on
the internet.1 Unlike cocaine and ecstasy, which have been
studied for decades, the effects of these new substances are
unknown and untested. This uncertainty combined with easy
accessibility presents a major challenge and a potential risk to
public health and public order.
And yet they are emerging almost weekly. The Daily
Telegraph reported that data presented to the Independent
Scientific Committee on Drugs showed 40 new substances had
emerged by the end of 2010, a new record.2 In 2009, a previous
record 24 new synthetic psychoactive substances were identified.3
There are now over 600 substances controlled under the Misuse
of Drugs Act (MDA) in the UK.4 With the emergence of
manufactured ‘legal highs’, this number is set to increase
drastically.
The ability of traditional approaches to drug control to
keep pace with these changes is now in question. As quickly as
policy makers make new substances illegal through the MDA,
others are being manufactured and put on the market. The
danger is that the next substance to emerge could be more
dangerous than the previous one. And the speed with which they
emerge leaves little time for experts to assess their potential
harm. Since the majority of these drugs are produced in China
and sold on the internet, their distribution and manufacture are
extremely hard to regulate. In the UK, enforcing drug control
laws is made increasingly difficult and costly, as only advanced
scientific analysis can distinguish between the multitude of white
powders and tablets. Moreover, traditional approaches to drug
control based on criminal enforcement can actually exacerbate
the harms caused by these drugs. For example, making new
substances illegal leaves the trade in the hands of unregulated
criminals who constantly adapt their methods of distribution and
sustain profitability by cutting their drugs with potentially
harmful substances.
As the MDA turns 40 years old this year, this report
investigates whether twentieth-century drug control legislation is
fit for the twenty-first-century drugs market.
Drug policy is a ‘wicked issue’
The challenges posed by new psychoactive substances provide an
opportunity to look afresh at drug control policy without
recourse to a rerun of older and redundant debates about
whether to be ‘tough or soft’ on drugs. Debate about drug policy
tends to reinforce the perception that there are only two extreme
options for policy makers: controlling drugs strictly through the
MDA with strong enforcement and punishments, or legalising
them. Those on each side of the debate present their view as
offering the single, most successful solution to the ‘drug
problem’ and drug policy. Yet evidence for the effectiveness of
either approach is thin on the ground.
The issue is one of framing. If drug policy is framed as ‘a
war on drugs’ then it is either won or lost and requires a level of
national sacrifice (wars are won or lost). If it is framed as the
‘drug problem’ then there is an implicit assumption that there is
a ‘solution’ (problems have solutions). An alternative way of
looking at the issue is to use systems thinking and consider drug
policy as a ‘wicked issue’ to which there is no solution, and no
winners or losers. Instead, one seeks an improvement to policy
that will be supported by people who otherwise disagree about
what is wrong and what the goals of policy are.
A new way forward
This is the aim of our project: to demonstrate the potential
benefits of taking a different approach to considering control of
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new substances, framing it as a ‘wicked issue’, and using soft
systems techniques to show that it is possible to identify areas for
action that people from both sides of the drug control debate can
agree would improve drug control policy.
To achieve this we convened two innovative soft system
workshops with 12 different key stakeholders attending each.
Participants included senior civil servants in relevant government
departments and agencies covering enforcement, health,
medicines, young people, education and consumer protection, as
well as pharmacologists and chemists, frontline workers from a
variety of charities, a young person peer mentor and advocates
from lobbying organisations from opposite sides of the drug
control debate. Together, these stakeholders examined the key
issues for control of new psychoactive substances (also known as
‘legal highs’) in a way that reflected their differing perspectives.
They identified areas of agreement about the elements of the
‘problem’ as well as options for action.
The project also involved an international review under-
taken by Professor Peter Reuter to look at the regulatory
approaches to drugs and new psychoactive substances taken else-
where, plus interviews with a wide range of experts in the UK.
Our soft system workshops approach demonstrated that it
is possible to get people to reconsider their perspectives, give
greater recognition to other viewpoints and find consensus on
ways forward. In keeping with the view that drug control is a
problem with no single solution we do not claim to have
provided the definitive answer for drug control policy. However,
the findings provide valuable insights on how and where policy
direction might be aligned with expert opinion and emerging
evidence.
Key policy issues
The project highlighted that:
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· When analysed from an international perspective, the latest wave
of new psychoactive substances has thus far been localised: there
have only been instances in a few countries where a new drug has
rapidly risen in prevalence on par with other illicit substances.
However, there are signs that their sale and use is spreading and
will continue to grow.5
· The cost of enforcement is likely to rise substantially and/or the
law become increasingly unenforceable with the number of
substances classified through the MDA rising dramatically.
· There is a fundamental and growing bias in the political and
regulatory system towards prohibition as a default option. This is
despite there being no conclusive evidence that classifying a
substance through the MDA reduces overall harms. This bias
may unintentionally increase harms, in addition to leading to
substantial financial costs in the criminal justice system.
· Information about the nature and effects of new substances is a
key issue for everyone involved in the drugs field: policy makers,
enforcement agencies and those engaged in providing prevention
and treatment. Yet knowledge about the new substances
becoming available is very poor and controlling a substance
under the MDA makes collection of the necessary information to
make genuinely informed decisions more difficult. Without
information on new substances as they become available, the
Government becomes susceptible to influence from media
campaigns and political pressures demanding action at critical
junctures.
· There is a wide range of different pieces of legislation besides the
MDA which can be utilised for controlling new potentially
harmful substances.
· The number of substances now controlled (over 600) and the
multiplicity of ways in which this is done is confusing and
appears often inconsistent, inefficient and ineffective.
· There are a number of potential benefits to taking a step back
and producing a simplified overarching control framework, such
as a Harmful Substances Control Act along the lines proposed
by the New Zealand Law Commission.6
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Implications for policy
The policy recommendations that emerged from the project
suggest three broad principles for improving drug policy and a
number of specific actions. The latter are in no way compre-
hensive but illustrate how a new approach might be used to
identify ways to improve drug policy.
Focus on achieving outcomes on which there is consensus
We need to shift the focus of debate away from stale arguments
about whether or not or how drugs should be classified to focus
on the broader outcomes that policy is seeking to achieve, such
as the desire to protect young people from the harms associated
with drug use. Our project demonstrates that in this way it is
possible to bring together people from different sides of the
debate to agree on a range of actions that could improve the
current situation; actions identified in the workshops have been
incorporated here.
The following areas for action were identified:
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· there should be continued investment and support for broader
intervention initiatives, delivered in schools and communities, as
well as family-based initiatives and mentoring schemes in order
to increase resilience to problematic drug use
· the Government together with local authorities and schools must
ensure that drug education is based on accurate information
delivered by individuals who will be perceived as credible and
authoritative
· a systematic framework for information collection should be
created to tap into the experience of drug users and frontline
workers, as an early warning system and source of knowledge
about potential harms and perceived benefits of new drugs
· the development and evaluation of outreach approaches, such as
amnesty bins in clubs and other venues where use of such drugs
is prevalent, should be supported to encourage people to adopt
less risky behaviours even if they do still continue to use, while
also providing valuable information about availability and purity
· there should be investment in laboratory-based investigation of
current and potential drugs of abuse.
Ensure a more balanced decision-making process and debate
There is a growing ‘fault line’ in the balance of decision making
about the control of new drugs that leads to a system that is
weighted in favour of the precautionary principle. This closes off
proper consideration of the relative harms of particular
substances and the harms that arise from banning these
substances. It also hinders the consideration of alternative
control measures. As a result, this bias may unintentionally
increase overall harms.
We recommend that the Government:
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· conducts more rigorous research into the full range of impacts
(including unintended harms) of the control and enforcement
elements of drug control and drug policy; while we acknowledge
the complexity of such an exercise, it is not methodologically
insurmountable, as similar assessments in areas as diverse as
climate change and health policy have shown
· gives greater consideration to identifying and assessing the
benefits (in addition to the harms) that individuals and society
derive from the use of psychoactive substances, including the
potential for substitution for more harmful substances. This
should be built into the formal assessment and advice process to
ministers and parliament; government legislation and
pronouncements recognise the benefits (beyond medicinal) of
the moderate use of alcohol, but fail to do so with other
psychoactive drugs
Consider other regulatory options for control
There has been insufficient attention and discussion given to
other control and regulatory mechanisms that have been used in
the past for other comparable substances. These alternative
control mechanisms could be utilised to respond to the challenge
of new drugs.
In the short term, the Government should:
· commit to a comprehensive assessment of the use and impact of
planned temporary banning powers; our project revealed
significant concerns among experts that the temporary ban could
be unenforceable, lead to other harms, and lead to a failure to
consider other control options
· give greater consideration to controlling the supply of new
psychoactive drugs through the wide range of consumer
protection legislation in some instances
17
In the longer term, Government and Parliament should:
· consider a radical reform of the measures for the control of
psychoactive substances to provide an overall and integrated
framework for controlling the supply of all potentially harmful
substances – including alcohol, tobacco and solvents – perhaps
through a Harmful Substances Control Act
In summary, it is 40 years since the Misuse of Drugs Act
1971 became law and the ‘drug problem’ is no nearer being
solved. The new psychoactive substances now being developed
pose new challenges while at the same time our understanding of
the problems associated with licit substances has grown.
Therefore it seems high time for a new approach. The drugs
debate is a hotly contested and polarised area and anyone
entering it runs the risk of being characterised as being on one
side or the other. However, it is clear that the ‘drug problem’ is
complex and multi-faceted and there is no simple solution to it.
We would suggest that it is time for a new approach to policy
making, legislation and debate on drugs issues focusing on
developing consensus and taking a more holistic view of
substance use while building better evidence about what works.
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In late 2009 and early 2010, the UK media reported widely on
the ‘unstoppable rise’ of a new and ‘legal’ drug:
methylmethcathinone (mephedrone).7 Similar to drugs like
amphetamine and cocaine in its effects and chemical
composition, mephedrone ‘emerged from nowhere’ to become,
according to one online survey, the fourth most popular drug
among British clubbers.8 However, mephedrone was different
from other drugs in that it was legal and could be purchased over
the internet at affordable prices, with no limitations on the size
of orders. Users could even get next day delivery.
At first, the amusing street names (meow meow, bubbles)
and this easy accessibility were enough to guarantee media
coverage and generate worry among policy makers. There soon
followed a series of drug-related deaths among young people,
reportedly tied to this new and unknown drug. While a media
frenzy commenced in the immediate run-up to the general
election of 2010, the Home Secretary Alan Johnson responded
by banning the substance by classifying it under the Misuse of
Drugs Act (MDA) following a swift review by the Advisory
Council on the Misuse of Drugs (ACMD).9
Since the mephedrone episode, there has been growing
concern about new psychoactive substances.10 Previously, BZP,
GBL and Spice had received attention from users and policy
makers alike but the apparent extent of mephedrone use, and the
speed with which it occurred, were unprecedented. Once
mephedrone was banned, other new and seemingly more
dangerous substances emerged, including NRG-1, Ivory Wave
and Benzo Fury.11
The Coalition Government’s response to the emergence of
new psychoactive substances is the creation of a temporary
banning order under the MDA. This is currently (early 2011)
passing through Parliament as part of the Police Reform and
Social Responsibility Bill. The temporary ban would control new
substances by placing them in a holding classification for a year,
allowing the ACMD to conduct research into its harms. At the
end of a year’s time, the substance would then either be banned
(permanently classified as A, B or C in the MDA), or regulated
through alternative means. Our research suggests there are a
number of concerns about the likely efficacy of this approach
which are discussed later.
New challenges
New psychoactive substances present policy makers with a
number of challenges. Unlike opium, cocaine and cannabis – the
effects of which have been intensively researched – new sub-
stances can emerge and be available for purchase over the
internet very quickly without any information on their compo-
sition, effects or safety. This speed to market makes it difficult for
toxicologists and other experts to give advice on the short- and
long-term effects of such drugs. The prospect of significant
numbers of people using untested and potentially dangerous
substances in an unsupervised or uncontrolled manner raises
serious public health concerns. And yet, the old approach to
controlling harmful substances – through the MDA – is
increasingly being seen as ineffective since the constant growth
and product ‘innovation’ in the synthetic drugs market allows
producers to stay ahead of the law.12 While heroin, cocaine and
cannabis originate mostly from organic sources, the composition
of synthetic drugs can be constantly altered to circumvent
legislation. As the list of substances continues to grow, the
financial and operational burden on enforcement agencies will
become increasingly unmanageable particularly in light of public
sector cuts.
There is a tendency, not only in the UK but internationally,
to propel any new substances into a control through criminal
penalties framework, even where the actual evidence of harms
may be limited (see Appendix I for short glossary of key drug
policy terms). This precautionary approach can have unintended
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consequences. Some commentators suggest that the growth in
popularity of new substances such as mephedrone and the
potential risk they pose could have arisen as a result of the
enforcement efforts on illicit drugs like ecstasy and the stricter
controls of chemicals like BZP13 (although others argue for
cyclical patterns in drug use with some drugs going in and out of
fashion). Such substitution has the potential to increase harms.
Some of the drugs that have been substituted for mephedrone
are more powerful and may be more harmful if taken in similar
doses. There is also emerging evidence that some people may
have substituted mephedrone for cocaine, and this may have
reduced cocaine-related deaths, although this requires
confirmation.14
The rapid development of new substances and their
availability on the internet requires a re-examination of drugs
control policies and the process by which potentially harmful
substances are controlled. The boundaries between recreational
drugs used for pleasure, cognitive enhancers, some medicines,
and other commercially used substances, are becoming
increasingly blurred. This poses considerable ethical and
practical questions about why one drug may be controlled by the
MDA and others through the medicines legislation or other
regulatory systems, such as the Intoxicating Substances Supply
Act 1985, which is essentially a piece of consumer protection
legislation. Moreover, the internet continues to confound
enforcement and regulation, not only for these new psychoactive
substances. Counterfeiting of legitimate medicines is increasingly
a global problem and is proving very difficult to police.
Adding to these new challenges is the fact that the UK
already has among the highest rates of illicit drug use in the
European Union, although more recently there has been a
downward trend.15 Illicit drug use continues to affect every part
of the UK and every social group, though some more so than
others. Approximately one in three people between the ages of 16
and 59 in the UK have used a controlled substance at some time
in their life, demonstrating that, although illegal, these
substances remain widely available.16 Drug use is also
increasingly intertwined with alcohol problems, which affect
21
communities, families and individuals. Clearly, something is not
working very well.
A new approach
In 2011 the MDA will be 40 years old. The world is very 
different now than it was in 1971. Over ten years ago the Police
Foundation Independent Inquiry into the Misuse of Drugs
(chaired by Dame Ruth Runciman), one of the first independent
assessments of the Act concluded, ‘The main aim of the law must
be to control and limit the demand for and the supply of illicit
drugs in order to minimise the serious individual and social
harms caused by their use.’17 Such an assertion seems equally
valid today even if circumstances have changed.
However, it is uncertain whether government can continue
to control emerging substances in the same way as it has done in
the past. There are now over 600 substances that are controlled
through the MDA, with new substances emerging virtually
weekly.18 According to the European Monitoring Centre for
Drugs and Drug Addiction (EMCDDA), there was a record 24
new synthetic psychoactive substances identified in 2009, and
another 15 had emerged by July 2010.19 The Daily Telegraph
reported that data presented to the Independent Scientific
Committee on Drugs showed 40 new substances had emerged by
the end of 2010, a new record.20
New drugs bring new demands on the resources of
enforcement and public health services. At a time of mounting
financial pressure, there is a question of government’s capacity to
respond to an increasingly long list of controlled drugs through
the MDA. Enforcement agencies including the police, borders
and customs face enormous practical challenges in light of
expenditure reductions and the costs of forensic testing in order
to secure possible prosecutions. There is also a risk that the
current recession and increasing unemployment, particularly
among young people, could lead to an even further rise in drug
use, though this is by no means a certainty.
The costs in other parts of the criminal justice system are
also already substantial. The current cost per prison place is
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estimated at £45,000 per year and the cost of Crown Court
process imposing a prison sentence is £30,500 per conviction.
With people convicted of drug offences making up 15 per cent of
male and 24 per cent of female sentenced prisoners in April 2010,
this suggests there are well over 10,000 people in prison for drug
offences at any one time. Given that many will serve less than
one year, the number being sentenced annually is still larger and
it can be seen that annual costs solely for drug control offences
in excess of a billion pounds are likely to be incurred.21 In
addition to this there are the wider costs to the society of other
drug-related offending by people with drug problems, which will
be even greater; it is estimated that between a third and a half of
the people in prison have drug problems.22
Meanwhile, there is a growing willingness in some
countries to handle control and enforcement in different ways.
This includes decriminalising drugs possession for personal use
in countries such as Portugal, the Czech Republic, Argentina,
Ecuador, Brazil and Bolivia.23 As the Police Foundation Inquiry
found in its research, a number of other countries in the
developed world including the Netherlands, Spain, Australian
states and Italy have tried various approaches including
administrative expediency in enforcement and prosecutions, and
the use of civil rather than criminal penalties for drug users.24
The experiences in these countries may hold transferable lessons
for policy makers, enforcement agencies and public health
professionals here in Britain. Among contested views about the
interpretation of evidence one thing is clear, the drug problem
has not spiralled out of control in those countries.
To some extent, UK governments have shown some
flexibility and adaptability in how they seek to control and
regulate psychoactive substances. For example, regulating the
misuse of solvents though the Intoxicating Substances (Supply)
Act of 1985; classifying anabolic steroids with no prosecution for
simple possession, as is also proposed under the temporary ban
category; increasing the use of fines and warnings for cannabis
possession; as well as the recent use of a ban under the Open
General Import Licence powers for the importation of
cathinones (the group of substances that includes mephedrone)
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before the classification of mephedrone in April 2010 and
recently recommended by ACMD for desoxypipradol (some-
times sold as Ivory Wave). Tobacco controls also illustrate the
ability of policy makers to take radical steps and, more recently,
new restrictions are proposed for alcohol sales. Such flexibility is
perhaps a classic British pragmatic response to changing circum-
stances and priorities. It shows that the law is not immutable and
there is a range of innovative and creative methods of control.
This project
The aim of this project is to use the lens of new psychoactive
substances to re-examine and explore how UK drug control
policy might utilise a broader range of policy options apart from
the established bans under the MDA. We have not sought to
replicate other valuable work that has examined how the MDA
might be incrementally improved (eg the Police Foundation
Independent Inquiry report or by the Science and Technology
and Home Affairs committees).25
We have also avoided reopening the debate about whether
existing drugs such as cannabis or ecstasy should be reclassified
or even whether the classification and scheduling system itself
should be revised or abolished. A stalemate of sorts has been
reached in those discussions: new drugs present new challenges,
which the current control system is increasingly ill-equipped to
deal with. The rapid arrival of new substances, technology and
distribution systems, allows us to examine carefully and consider
how a different approach to their control might work in practice.
The project consisted of two main elements. First, we
commissioned an international review to look at the experiences
of emerging ‘legal highs’ in the UK and abroad and analyse the
different regulatory approaches that countries have thus far
taken to new psychoactive substances. This review was
conducted by Peter Reuter, Professor in the Department of
Criminology at the University of Maryland and a founder of the
RAND Drug Policy Research Center.26
Second, we convened 24 key stakeholders for two day-long
workshops addressing the ‘legal highs’ issue from two different
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starting points. We also conducted qualitative interviews with ten
drug experts in the UK. The workshops made use of an
innovative systems approach pioneered in a project concerned
with youth nuisance on deprived estates and outlined in previous
Demos reports System Failure (2001) and Connecting the Dots
(2009).27 Our aim was to bring together a range of experts and
stakeholders who do not meet regularly to engage in a
comprehensive discussion about how drug policy can tackle the
new challenge of ‘legal highs’.
The workshops were conducted under Chatham House
Rules, and because of the sensitivity of the topic participants will
remain anonymous. Participants included senior civil servants in
relevant government departments and agencies, covering
enforcement, health, medicines, young people and education,
and consumer protection, as well as pharmacologists and
chemists, frontline workers from a variety of charities, a parent
activist, a young person peer drug mentor, and advocates from
lobbying organisations from opposite sides of the drug control
debate.
Too often, policy is made and implemented in isolation
from other stakeholders. This can have unintended consequences
and result in policies that work at cross purposes. The aim of the
workshops was to bring to the surface the different perspectives
represented by those attending and foster a more constructive
debate.
The first workshop explored how best to protect young people
from new psychoactive substances. The second workshop explored
what steps could be taken to control the availability of new psychoactive
substances.
Our aim in this report is to demonstrate that it is possible
to gain agreement from people with contrasting perspectives on
actions and improvements to policy. Drug policy is already
fraught with complexity, value conflicts and high stakes. The
emergence of new psychoactive substances complicates drug
policy further through a new set of challenges.
We argue that a different approach to the development of
drug policy is needed: a fresh approach that gives greater
consideration to our pluralist society in which people hold many
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different and opposing views, so evidence to underpin policy
making is vital, even if it is not perfect. Instead of arguing for
one side of the debate over another in a zero-sum game, we
advocate the need to find better consensus on areas that more
people can agree on and then seek to make improvements to
policy.
The report structure
In the first chapter, we look briefly at the history of psychoactive
substances in order to put the emergence of new ‘legal highs’
into context. This chapter also includes previous research into
‘legal highs’ as well as the findings from Peter Reuter’s report
into the experiences of ‘legal highs’ in other countries.
In the second chapter, the focus shifts to the policy context.
It includes a brief history of drug control policy, discussion of
the recent debates on drug policy and lessons from abroad on
dealing with the emergence of new psychoactive substances.
Chapters 3 through 5 focus on the soft systems approach to
drug policy and the findings from the workshops. Chapter 3
describes the soft systems methodology and the
conceptualisation of the ‘drugs problem’ as a ‘wicked issue’.
Chapter 4 presents the findings from the first workshop.
This includes the areas of broad agreement on non-legislative
approaches that can help protect young people from the harms
of emerging new substances.
Chapter 5 presents the findings from the second workshop,
looking specifically at legislative options for controlling the
emergence of new psychoactive substances.
In Chapter 6 we offer recommendations for policy.
Introduction
1 The ‘drug problem’ and
new psychoactive
substances
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The fundamental urge to alter our consciousness in significant but
controllable ways is, it seems, part of our hard-wiring.28
When considering the issue of drug use in society or the
‘drug problem’, most people tend to think of a relatively small
collection of core illicit substances: heroin, cocaine, cannabis,
LSD, ecstasy and amphetamine. People rarely include similarly
harmful (and potentially addictive) substances such as alcohol
and tobacco. They are probably even less likely to call to mind
solvents, poppers, nitrous oxide, ‘study drugs’ or even caffeine.
However, all of these substances have psychoactive, intoxicating
or sense-heightening effects for humans. They are thus, to
varying degrees, subject to use, misuse and addiction by
individuals seeking to ‘get high’ or get ahead.
Psychoactive substances in society
While our review is focused on new psychoactive substances, one
cannot ignore the evolution of drugs and drug use in society.
Psychoactive substances have played a role in much of human
history. They have provided tonic to pain and disease, played an
integral role in social and religious ceremonies in some societies,
and fulfilled a desire to alter our consciousness. Researchers have
discovered implements for inhaling drug fumes or powders in
South America that can be dated back to between 400 BC and
100 BC.29 Beer has been dated as far back to Neolithic times
(10,000 BC), and ancient Chinese tools for making wine have
been discovered. The benefits and harms associated with alcohol
have been debated at least from the ancient Greeks through the
1800s and early 1900s to the present. The use of opiates in
various forms also has a long history, from evidence of the
consumption of poppy seeds in c 2500 BC, through widespread
use in China from the eleventh to the twelfth centuries AD as a
medicine and later recreationally, and the introduction of
laudanum and other opium products to the practice of medicine
in Europe from the sixteenth century onwards in Europe.30 And,
of course, the rapidity with which the use of caffeine (in the form
of tea and coffee) and nicotine (from tobacco) spread once they
were introduced from the New World provides testament to our
acceptance of the use of psychoactive substances and of the long-
term nature of some of the harms associated with them.
In light of this history, and the persistence (and even
increase) in the number of people using a range of psychoactive
substances for a variety of reasons, the idea of a ‘drug free’
world, as envisaged by previous drug policy campaigns of the
1980s, seems quixotic, if not unnatural and most certainly
unachievable. Nevertheless, to highlight the seemingly basic
human desire to ‘alter our consciousness in significant but
controllable ways’ should by no means imply that this is
something that all humans do, or should do. The number of
people who regularly use illicit substances is quite small
proportionally. While estimates of drug use are an inexact
science, the authoritative numbers suggest that anywhere
between 3 per cent and 6 per cent of the world’s population used
illicit substances at least once in 2008. The United Nations
Office of Drugs and Crime (UNODC) estimates that there are
anywhere between 16 million and 38 million problem drug users
(who are dependent on drugs, or using the most dangerous
drugs such as injected heroin) in the world. The majority of
people who use illicit drugs – approximately 80 per cent – use
cannabis, which remains the most widely used illicit substance in
Europe and here in the UK.
In many parts of the UK, illicit drug consumption may be
perceived as a ‘common’ but not a ‘normal’ activity, at least for
most of the population. Of course this differs according to age
and locality. By comparison, consumption of licit substances
such as tobacco and alcohol is significantly higher and can be
said to be a ‘normal’ activity in the UK and abroad.
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Alcohol and tobacco: the other ‘legal highs’
Compared with many other European countries, the UK appears
to have a particular problem with excessive drinking, especially
among young people. Consumption of alcohol in the UK has
increased by 19 per cent over the last three decades.31 There are
now an estimated 10.5 million adults in England who drink
above sensible limits and 1.1 million adults in England have a
level of alcohol addiction.32 These numbers dwarf the number of
people in the UK who use (not necessarily in a problematic way)
illicit substances. Moreover, while the number of smokers has
fallen substantially over the past decade, there are still around 10
million adults in the UK who smoke cigarettes: approximately
one in five men and women smoke. It has been estimated that
over 100,000 people a year in the UK die from smoking-related
diseases.33
As discussed further below, there has been increasing
attention in recent decades on the harms of licit substances such
as alcohol and tobacco. According to recent analysis by the
Independent Scientific Committee on Drugs, alcohol is the
fourth most harmful drug to the user, and the most harmful to
society as a whole, making it more harmful than both heroin and
cocaine.34 While there is debate about the particular
methodology used to reach this assessment there is no doubt that
the substantive point about the growing harms of some types of
alcohol use is broadly accepted.
New substances and global factors affecting drug use
While the history of psychoactive substances in human society is
long and varied, drug use has changed drastically over the past
100 years and more people are using a broader range of
substances than ever before. Changes in patterns of drug use are
the result of a combination of technological advancements,
changing social norms, growing wealth yet widening economic
inequalities, civil strife in other parts of the globe along with
unscrupulous suppliers and corrupt officials.
Set against these deep undercurrents, we highlight three
factors that underpin the emergence of new and varied
psychoactive substances and the current dynamism and flux in
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the drugs market. The result is a difficult problem made
significantly more intractable. These trends include:
The ‘drug problem’ and new psychoactive substances
· the rise of ‘manufactured drugs’
· the internet
· changing cultural norms towards intoxication.
The three trends identified above suggest that the problem
of new psychoactive substances will continue to influence
patterns of drug use in the coming decades.
The rise of manufactured substances
While the list of ‘legal highs’ presented in the introduction all
emerged in the past ten years, the appearance of new synthetic
drugs is not an entirely twenty-first-century phenomenon.
Alexander Shulgin, an author and influential biochemist in the
drugs field, predicted the diversification and increasing number
of psychedelic and synthetic substances in the 1960s. There has
been considerable growth in the different types of drugs since
then: between 1961 (when the UN Single Convention on
Narcotic Drugs was first passed) and 1995 the number of
prohibited substances rose from 85 to 282.35
Synthetic drugs – manufactured by chemists in laboratories
– have risen rapidly in prevalence over the past two decades.
Although MDMA and other ecstasy-group drugs were first
developed in the early 1900s, recreational use of ecstasy
exploded in the 1990s, particularly in Europe and the USA.36
Manufactured amphetamine-group substances, including ecstasy
and related drugs, are now the second most used illicit substance
behind cannabis. The UNODC predicts that the number of
amphetamine-type substance users globally is likely to surpass
the number of opiate and cocaine users combined in the near
future.37
There are a number of reasons for the growth in the market
for these drugs, including changing social norms, youth culture,
the manufacturing process, the ease of substituting precursor
chemicals and psychoactive substances, and the convenient
methods for taking these drugs (pills versus injecting, snorting
or smoking).
Additionally, the enforcement strategy against
manufactured substances is more complicated. Unlike the
cultivation of coca and poppy plants, manufactured drugs can be
produced closer to consumer markets with shorter distribution
chains.38 They are also impervious to remote sensing, unlike
poppy plants, cocoa bushes and indoor cannabis farms.39
Moreover, enforcement efforts must contend with not only the
final product, but also the distribution of precursor chemicals.
Ecstasy can be manufactured using a variety of precursor
chemicals and a variety of manufacturing methods, which makes
replacements easy to find, and ensures greater flexibility in the
manufacturing process.40
The rise of manufactured drugs has led to an explosion of
synthetic drugs designed to mimic the effects of illicit substances.
New substances have included synthetic cathinones, synthetic
cannabinoids, and new cocaine and amphetamine-like synthetic
derivatives, among a variety of other substances. These are the
new generation of ‘legal highs’. Coinciding with this is a trend
towards increasing levels of deception and confusion in the
actual composition of marketed drugs. In the European drugs
market, tablets sold as ecstasy increasingly contain other
substances, including piperazines like BZP, mCPP and TFMPP.41
Some of these substances are not under domestic or international
control, so constitute ‘legal highs’.42 Mephedrone has
increasingly been sold as ecstasy or as a suitable replacement to
ecstasy, before and after its control via the EMCDDA and
national legislation.
The speed with which this shift has taken place is alarming.
UNODC reports that in 2006, 10 per cent of tablets sold as
ecstasy in the EU contained mCPP. By the end of 2008 this
figure had risen to 50 per cent in countries with large markets for
ecstasy.43 This increasing confusion and uncertainty poses a
number of challenges to enforcement and public health agencies.
It also puts a high premium on quick and easy drug-testing
facilities to determine the composition of drugs.
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The influence of the internet
The ease with which new drugs can be synthesised and
manufactured is matched by the efficient and difficult to regulate
distribution methods now provided by the internet. As with
every other aspect of life in the twenty-first century, the internet
has significantly impacted on the distribution of drugs and drug
use. Information about new drugs was previously disseminated
through word of mouth or traditional media. Now, information
about new drugs can be transmitted to a larger number of
people more quickly than ever before.
This is likely to result in a wider range of people being
aware of and likely to use an increasingly wide range of sub-
stances. Indeed, with ‘legal highs’, groups of people who might
be put off using drugs by a lack of contact with drug dealers, can
gain access to a drug and purchase it in much the same way they
now purchase many other goods over the internet.
The internet has also facilitated the emergence of new
manufacturing and distribution centres (most significantly from
China and India) by providing them with global reach into the
lucrative and seemingly insatiable market for drugs in Europe
and North America. Motivated by profit and effectively out of
reach of these countries’ drug laws, research chemists and
entrepreneurs have emerged to supply the Western world’s
demand for drugs. As a result of this change in the supply side of
the drug market the frequency and speed with which new drugs
can emerge is significantly greater. The same dynamic is at the
root of the rise of counterfeit medicines.
Changing cultural attitudes towards intoxication
Reuter suggests there is an increasing tolerance in Western
society for ‘altered states of consciousness’.44 However, this does
not necessarily mean that use rates of illicit substances like
cannabis, cocaine, heroin and ecstasy are rising. Indeed, recent
reports suggest that trends in cannabis consumption indicate
stable or declining levels of use.45 The UNODC suggests that
heroin use is decreasing in most West European countries and
although the trend in cocaine use varies between different
countries, for the most part use appears stable.
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In this context the difference between a ‘good’ high (eg
alcohol in moderation) and a ‘bad’ one (eg ecstasy in
moderation) is becoming harder to explicate.46 In the USA, as
elsewhere, there has been a growing acceptance of marijuana use,
particularly for medical purposes. Simultaneously, there has
been increased attention to the social and health harms of
alcohol consumption. This blurring of the lines has led many
experts and members of the public to question why one harmful
substance can be purchased in a shop, while possession of the
other is punishable by prison and a criminal record.
Such changing attitudes and perceptions may also con-
tribute to the increasing patterns of ‘poly drug’ use (the use of
many different kinds of drugs simultaneously), particularly in
Europe. According to the EMCDDA, almost all patterns of ‘poly
drug’ use include alcohol, and it is likely that a significant
proportion also include cannabis.47 In part, such explanations
have given rise to new political calls for increased personal
responsibility in substance-using behaviours.
Finally, the significant growth in the ‘study drug’
phenomenon – particularly in the USA – means that large
numbers of young people are using drugs not only to get high,
but also to get ahead. The ‘study drug’ phenomenon is one
aspect of a growing problem with the misuse of prescription
drugs, including painkillers and antidepressants.
‘Legal highs’: the new generation of manufactured
drugs
The rise of new psychoactive substances (aka ‘legal highs’) in the
twenty-first century is an extension of these underlying trends.
Some of the best-known examples of this new generation of
manufactured substances are GBL, BZP (see box 1), Spice,
mephedrone (see box 2), NRG-1 (see box 3), Benzo Fury and
Ivory Wave. Not all of these substances are new drugs which
have just been created by DIY, entrepreneurial chemists. Some of
them are manufactured for other industrial uses (eg GBL and
other solvents), but have been discovered to have intoxicating
effects. A recent article in the International Journal of Drug Policy
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notes three types of ‘legal highs’: organic plants, synthetic
substances and semi-synthetic substances derived from natural
oils.48
Box 1 Case study: BZP (1-benzylpiperazine)
BZP became the fourth most widely used drug in New Zealand
in the period 2004–2008.49 Originally developed for
veterinary purposes, BZP first appeared in ‘party pills’ in
2000.50 Surveys in New Zealand have shown that most users
consume BZP with alcohol and other psychoactive substances.
Only a few direct studies have been made on the
physiological properties of BZP in humans. Available
information derives mainly from indirect sources, for example,
from self-reports of users on internet sites, clinical observation
of intoxicated patients, or post-mortem material.
In 2006 and 2007, New Zealand’s Expert Advisory
Commission on Drugs concluded that the risks to users were
moderate. Acute problems largely came from combining BZP
with alcohol and other drugs, as well as the variability of
potency (the latter may have been mitigated had there been
processes for formal regulation).51 As mentioned above, many
BZP tablets and capsules also contain TFMPP (1-(3-
trifluoromethylphenyl) piperazine).
How prevalent are new ‘legal highs’?
Reuter’s research into the international experience concluded
that the problem of new psychoactive substances (‘legal highs’)
has been modest and localised thus far. There have been few
instances in which a new psychoactive substance, not covered by
existing regulations or laws, has become a significant problem in
terms of widespread use on a par with illicit substances like
ecstasy and cocaine. The two most prominent examples are BZP
in New Zealand and mephedrone in the UK.
Nonetheless, the market for ‘legal highs’ is moving quickly.
At the beginning stage of writing this report in December 2010,
the issue of ‘legal highs’ and a number of the substances most
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prominent in Europe were essentially unknown in the USA. A
search of the Drug Abuse Warning Network (DAWN), which
lists known psychoactive substances in the USA, by Reuter at the
end of 2010 found no mention of BZP, Spice, mephedrone or
naphyrone, using both street and technical names.52 However, in
January and February 2011 there were media reports that the
problem is of growing concern in the USA.53 The Washington Post
reported recently that cathinone derivatives are being advertised
in the USA primarily as ‘bath salts’, rather than ‘plant food’ as in
the UK and Europe. In March 2011, the US Government
announced that it was using emergency scheduling powers to
ban five synthetic cannabinoid chemicals, which can be used to
comprise Spice.54
Motivations for using ‘legal highs’
There have only been modest levels of research into the profile of
‘legal high’ users, and their motivations. Who is using these new
substances, and why? Do new ‘legal highs’ simply present more
choice for those who already use a range of illicit drugs and
alcohol, or do they appeal to a new cohort of users who would
normally be discouraged from illicit activity?
There is a small but growing body of primary research into
use of mephedrone particularly in the UK. There have been
three quantitative surveys into mephedrone use. Two were
annual Mixmag surveys (online self-selecting surveys of clubbers
and festival goers that hence represent a particularly high drug-
using group within the population), including the 2010 survey
which first revealed that mephedrone had become the fourth
most popular drug among the 2,000 people who responded to
the survey. The other survey was conducted in Scotland, with
over 1,000 school and college or university students responding,
showing that one in five had tried mephedrone.55 There has 
also been a handful of smaller-scale qualitative research studies
with mephedrone users.56 This includes research before and
following the classification of mephedrone in April 2010, which
gives some insight into the effect of classification on changing
patterns of use.
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Box 2 Case study: mephedrone (4-methylmethcathinone)
Mephedrone is a synthetic cathinone. It is the most recent ‘legal
high’ to attract significant media attention, particularly in the
UK, which accounted for 88 per cent of European seizures of
the drug in 2010.57 Some research suggests that mephedrone
emerged in part as the consequence of the declining quality of
ecstasy.58
The drug first emerged in the UK in 2008, and grew in
prevalence rapidly. Two seizures were reported in 2008, 20
seizures in early 2009 and up to 600 seizures in the latter part
of 2009.59 A survey of EU member states found that only the
UK and the Netherlands had made substantial seizures; the
nine others (Estonia, Finland, Germany, Ireland, Italy,
Latvia, Romania, Slovenia and Slovakia) with any seizures
reported totals of 2–325 grams. Ireland and the UK reported
‘legal importations’ of mephedrone available for purchase in
‘head shops’ or over the internet advertised as a plant food.
Europol and EMCDDA report that there is little evidence of
European processing or trafficking in mephedrone. Evidence
suggests mainly legal production and distribution from Asia,
namely China.
An internet search in December 2009 revealed at least 31
websites selling mephedrone, a majority of which were based in
the UK.60
There is some very limited research into the prevalence of
mephedrone within the UK, and the profile of users. The most
significant research in scale comes from an annual survey of
drug using by the European clubbing magazine, Mixmag.61
This online survey consisted mainly of self-selecting individuals
who are active in the club scene and therefore probably yields
figures that show greater levels of drug use, than among even
the wider clubbing population. The survey had 2,220
respondents, of which 65 per cent were male and 81 per cent
were employed, mostly aged 18–27. The Mixmag survey
revealed that in less than a year, mephedrone had become the
fourth most popular drug among those British clubbers
sampled, with 42 per cent reporting ever having taken the
substance (lifetime prevalence), 34 per cent use in the past
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month, and 6 per cent use weekly. There has also been a small-
scale qualitative study of ten mephedrone users in
Middlesbrough, UK. This consisted of nine men and one
woman, all of whom were regular or occasional users of other
drugs (mainly alcohol, cannabis, ecstasy). Among this sample,
mephedrone was mainly a weekend indulgence at parties or
nightclubs, with most people mixing the drug with alcohol
and/or cannabis. Users describe stimulant and hallucinogenic
effects, with negative effects including cravings, skin rashes,
vomiting, insomnia and/or amnesia; several respondents
experienced some of these effects.
Knowledge of the adverse effects of the substance is slight,
as the EMCDDA reported in 2010: ‘there are no published
formal studies assessing the psychological or behavioural effects
of mephedrone in humans’.62 As with BZP, much information
is based on informal sources such as user reports.
Professor Fiona Measham and colleagues conducted
research into the reasons for the growth in popularity of
mephedrone in particular.63 People choose to take ‘legal highs’,
or any drugs for that matter, for a number of factors including:
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· legality
· price
· purity
· convenience and availability
· effect
Their research suggests that displacement resulting from
fluctuations in the supply of illegal drugs is a key issue in
understanding changing patterns of drug use. They argue that
there was a ‘growing disillusionment with the quality of street
drugs throughout the 2000s’ because of the lack of purity of
drugs like cocaine, ecstasy and MDMA. Cocaine purity
reportedly dropped from 60 per cent in 1999 to 22 per cent in
2009, while analysis of seized ecstasy pills in 2009 showed that
half contained no ecstasy, but rather BZP or caffeine. There have
also been decreasing purity levels of MDMA, probably as a result
of enforcement successes and stricter security.
Additionally, availability appeared to be a more significant
motivation than legality for using mephedrone. Users were less
concerned about whether they were doing something illegal than
they were about the ease with which the lack of any regulation
made these drugs available. Curiosity to experiment with
something new was also a cited factor for use.64 Box 3 presents a
case study of the drug naphyrone, which emerged around the
time of mephedrone and was often marketed by sellers as a
replacement following the banning of mephedrone.
Box 3 Case study: NRG-1 (naphyrone)
Naphyrone is a high-potency cathinone. Before it was banned
in July 2010 as a class B drug within the Misuse of Drugs Act
(MDA), it was largely sold in the UK through the internet. Its
harms are thought to closely equate with those of mephedrone,
but it is much more potent; a standard dose of naphyrone is
one-tenth that of mephedrone.
The majority of samples of supposed naphyrone actually
contain mephedrone and other related compounds.65 The
ACMD speculates that this may be the consequence of
mephedrone distributors dumping their product after it was
classified in April 2010.66
Naphyrone has significant potential for abuse: according
to Reuter, naphyrone is a triple-uptake inhibitor like cocaine
(with ten times the potency) rather than a single-uptake like d-
amphetamine and MDMA, which means that it affects all
three neurotransmitters linked to depression: serotonin,
norepinephrine and dopamine.67 Moreover, the lack of
transparency over its content, and the much smaller difference
between safe and lethal dosage compared with mephedrone,
could potentially lead to overdoses.
These findings concerning motivations do not necessarily
hold for all ‘legal highs’, but depend on the quality of the effect,
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as well as the quality of illicit substances. For example, Measham
et al cite research around the motivations for using Spice, finding
that legality was the most significant motivator. Spice is a set of
herbs with some synthetic cannabinoids added. It was first
identified in Sweden in 2007, though it had been available at
least since 2004. Like other ‘legal highs’, Spice has been an
internet phenomenon, where it is advertised for purposes other
than consumption (eg incense, bath salts). It can contain a large
range of cannabinoid substitutes, of which many of the harms
are unknown, and often does not contain the materials identified
on the package. Once Spice was given comparable status within
the MDA, most users reportedly switched back to cannabis.
Participants said this was because the effects of Spice were not as
pleasurable as cannabis.
The impact of banning ‘legal highs’
Meanwhile, there is evidence to suggest that the use of
mephedrone has continued despite its classification. Research by
McElrath and O’Neill, based on semi-structured interviews with
23 people in Northern Ireland who used mephedrone, suggests
that while distribution over the internet has diminished and
prices have risen, mephedrone remains available and sought
after.68 While the majority of the sample purchased mephedrone
from friends or dealers before the ban, there was still greater
reliance on dealers following the ban. Interestingly, those in this
sample were reluctant to purchase mephedrone in ‘head shops’
or over the internet before the ban, for fear of stigmatisation.
This suggests that legal status was irrelevant to the stigma of
purchasing or using the substance, and the perceived harm. As
McElrath and O’Neill note, the lack of impact of legality on the
perception of harm contrasts with the experience of BZP in 
New Zealand. As discussed in the next chapter, the ambiguous
legal status of BZP in New Zealand led some to conclude that it
was safe. However, this difference may be because the New
Zealand research included higher numbers of young people and
drug novices, whereas the Northern Ireland research included a
range of older people (it included those aged 19–51), most in
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professional occupations and long-standing recreational 
drug users.
The latest Mixmag annual survey for 2011 shows a relatively
mixed picture of the effect of the ban on use.69 On the one hand,
there was a higher proportion (61 per cent) of respondents who
had ever tried mephedrone compared with the previous year
before the ban (42 per cent). Users this year were also more
likely to have used it in the past 12 months, though slightly less
likely to have used it in the previous month. Most notably, 75 per
cent of those who had ever tried mephedrone had done so since
it was banned in April 2010. The survey also suggests a
displacement effect as a result of the ban, with 30 per cent of
respondents saying they used more ecstasy as a result of the ban,
and 19 per cent saying they used more cocaine as a result of the
ban.
On the other hand, 56 per cent said their use had decreased
or stopped following the ban, while 33 per cent said that the ban
had no effect. The ban also appeared to decrease the availability
of mephedrone and increase its price. It is perhaps most
worrying that prevalence of use increased while the purity of the
drug decreased. Before the ban, 90 per cent of respondents had
thought the purity of mephedrone was either good or excellent,
while 30 per cent suspected it was cut with something else.
Following the ban, the percentage who suspected mephedrone
was cut with other substances rose to 80 per cent.
The ‘legal high’ challenge for policy makers
Unlike cocaine, cannabis, heroin, alcohol and tobacco, we know
much less about the impact of this new generation of
psychoactive substances. So far, it seems, new psychoactive
substances have remained on the fringes of the drug-using
community. The two exceptions appear to be mephedrone in the
UK and BZP in New Zealand. Nonetheless, the problem appears
to be growing and the rise of these new substances presents
policy makers with a number of challenges. The next chapter
looks at the policy context, and the response to ‘legal highs’ thus
far. As seen above, research suggests that the growth of these new
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substances may stem in part from successes in tackling illicit
substances like ecstasy. Moreover, it seems that banning
mephedrone has had only a marginal impact on use, and may
even increase the harm it causes by decreasing transparency
about its content.
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2 Drug control and the
policy response
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All governments seek to control the availability of harmful
substances in society, and there are a number of ways in which a
government can do this. In the UK, since 1971 the Misuse of
Drugs Act (MDA) has been the primary legislation for
controlling psychoactive substances, primarily through police
enforcement. However, there is other legislation in the UK that
controls harmful substances, including the Intoxicating
Substances Supply Act and the Medicines and Health Act and
the various Licensing Acts governing sale of alcohol in different
parts of the UK.
The choice of regulatory option depends on a number of
factors:
· the toxicity of the substance
· the prevalence in use and the desirability of its effect
· historical and cultural precedents
· ‘beneficial’ medicinal or industrial uses
Regulatory options are constrained by international and
supranational agreements. There are three UN conventions on
drugs. The first is the 1961 Single Convention on Narcotic 
Drugs, which applies to opiates, cocaine and cannabis. The
second, the Convention on Psychotropic Substances in 1971
extended controls to LSD, amphetamine, barbiturates and
benzodiazepines. Third, the Convention Against Illicit Traffic in
Narcotic Drugs and Psychotropic Substances in 1988 focused on
aligning international efforts to tackle international drug
trafficking.
The UN’s Single Convention on Narcotic Drugs 1961 and
its efforts establishing the Convention on Psychotropic
Substances (ratified in 1971) informed UK policy and the
development of the classification system under the MDA. James
Callaghan, then Home Secretary, told Parliament in 1970 that in
developing the ABC classification system the Government had
used the UN Single Convention on Narcotic Drugs and
guidance provided by the World Health Organization to place
drugs ‘in the order in which we think they should be classified of
harmfulness and danger’. Box 4 presents a brief history of UK
drug control policy.
Box 4 Brief history of UK drug control policy
Reuter and Stevens present the history of UK drug policy in
four phases, covering pre-1916, 1916–1928, 1928–1960s and
the 1960s onward.70
The first major piece of UK legislation was the
Dangerous Drugs Act 1920, which limited production, import,
export, possession, sale or distribution of opium, cocaine,
morphine or heroin to licensed persons. Before this, legislation
of potentially harmful substances was limited to the 1868
Pharmacy Act, which was the first regulation of poisons and
dangerous substances, limiting sales to chemists, and the 1908
Poisons and Pharmacy Act, which specifically included coca in
regulations on sale and labelling.
The Dangerous Drugs Act restricted sale and distribution
generally, but allowed for the prescribing of cocaine and heroin
to addicts by licensed doctors and pharmacists. Known as the
British System for its uniqueness compared with other
countries’ legislation, this system functioned until the 1960s
when abuses of the system combined with other external factors
to hasten its revision.
In the 1960s, the UK passed two additional Dangerous
Drugs Acts (in 1964 and 1967) driven by the cultural
liberalisation of drug taking, particularly among young people.
Under these acts, drug offences were penalised equally, with no
recognition of differing relative harms. These acts generated
criticism because of the harsh punishments prescribed for
cannabis possession. In response to a publicity campaign by
celebrities and experts in the UK, the Wootton Committee was
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established and argued for the abolition of imprisonment for
cannabis possession. This eventually led to the MDA in 1971,
which made the distinction between sales and use in scope of
punishment.71
The Misuse of Drugs Act 1971
In addition to creating a classification system that used the harm
caused by a drug as a means of guiding sentencing, the MDA
also created the Advisory Council on the Misuse of Drugs
(ACMD) as an independent body to provide guidance on the
classification of substances according to their harms. The MDA
sought to combine a sense of proportionality with a commitment
to evidence-based policy making. The Act makes it a statutory
requirement that the ACMD is consulted to assess harms before
making amendments to a drug’s classification (although its
findings do not have to be followed by the Secretary of State). In
addition to a drug’s class under the MDA (consisting of A, B and
C categories), the Act also provides a scale of varying controls
(known as Schedules) to allow a substance’s use for medical
and/or research purposes. Table 1 lists the drugs included in the
British Crime Survey and their classification under the MDA;
table 2 lists the drugs included in the schedules determining
medical use controls under the MDA.
The unintended harms associated with drug control
Much of the criticism of current drug policy approaches rests on
the failure of enforcement-led policy to prevent the availability
and use of illicit substances like cannabis, cocaine, heroin and
ecstasy despite huge amounts of expenditure in time, money and
resources. A number of high profile evaluations and reports have
pointed to the diminishing returns to supply side approaches
that involve enforcement and incarceration. According to a UK
Prime Minister’s Strategy Unit report from 2003, ‘even if supply-
side interventions were more effective, it is not clear that the
impact on the harms caused by serious drug users would be
reduced’.72
45
Another major criticism of current drug control measures
arises from an increasing recognition that prohibition itself can
result in harm. As Antonio Maria Costa recognised when he was
executive director of UNODC, banning substances can have a
wide range of negative consequences, including:
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Table 1 Drugs included in the British Crime Survey and their
classification under the Misuse of Drugs Act (July 2010)
Classification Drug
Class A Powder cocaine
Crack cocaine
Ecstasy
LSD
Magic mushrooms
Heroin
Methadone
Methamphetamine
Class A/B Amphetamines
Class B Cannabis (since January 2009)
Class B/C Tranquilisers
Class C Anabolic steroids
Ketamine (since April 2006)
Not classified Amyl nitrite
Glues (including glues, solvents, gas or
aerosols)
Source: Hoare and Moon, Drug Misuse Declared73
· the creation of an expansive and powerful criminal black market,
with associated violence and other crime
· black market drugs being more likely to be cut with other
substances to increase profit, leading to uncertainty around safe
dosage levels and exposure to potentially harmful contaminants,
resulting in health harms or even death
· the criminalisation of people (particularly ethnic minorities and
low income communities), including young people, if caught in
possession of illicit substances that are nevertheless in
widespread use
· the stigmatisation of people suffering from addiction, which may
impede access to treatment and rehabilitation75
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Table 2 Drugs included in the schedules determining medical use
controls under the Misuse of Drugs Act
Schedule Level of Description Drugs
control
1 High No recognised medicinal Ecstasy, LSD, cannabis
use
2 High The most potent and Heroin, morphine, 
harmful drugs that can be cocaine
used clinically
3 Medium Lighter controls on storage Buprenorphine, 
and administration Temazepam
4 Medium Lighter controls on storage Most tranquilisers, 
and administration; lesser ketamine, steroids
controls on prescription 
than Schedule 3
5 Low Contains very low levels of Kaolin and morphine
controlled drugs that can be 
bought over the counter
Source: Home Office, Review of the UK’s Drugs Classification
System74
Current drug control measures also give rise to a number of
displacement effects. For example:
· policy displacement (high expenditure on enforcement at the
expense of other policy areas, such as public health)
· geographical displacement (enforcement efforts concentrated in
one country leading to the development of new producer
countries or distribution routes
· substance displacement (restricting the availability of some drugs
leading to the development of new drugs)
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At the street level, successful enforcement initiatives can
have the effect of raising the price of drugs, which may cause
dependent users to commit crime in order to obtain their ‘fix’. It
can also affect the purity of drugs and lead to overdosing among
drug users and the introduction of potentially harmful cutting
agents. Finally, criminal drug laws often disproportionately
affect certain communities, particularly those in lower income
neighbourhoods. As the ACMD highlighted, the development of
serious health and social problems as a result of heroin injecting
in the 1980s was largely associated with social disadvantage.76
This inequity also extends to different ethnic groups as has been
well documented in the USA,77 and research shows a similar
picture in the UK, with black people six times more likely than
white people to be arrested for drug offences and 11 times more
likely to be imprisoned despite there being no evidence that
black people are more likely to use or deal drugs than white
people.78
Nevertheless, it remains extremely difficult to quantify the
harms of drug control policy (relative to the harms of drugs
themselves). In a recent debate during the scrutiny stages of the
Police Reform and Social Responsibility Bill in Parliament, the
Home Office drugs minister, James Brokenshire MP, argued:
The impact of domestic and international prohibition policy on levels 
of consumption and production globally is key in any meaningful 
assessment and analysis of the 1971 Act. We do not accept that meaningful
figures can be ascribed to the likely public and individual health cost or 
that it is possible to properly assess the impact of drugs on productivity 
and industry or on industrial or traffic accidents. Those fundamental
difficulties point up the question of whether the task is an appropriate use 
of research funding. In our judgment, it would not be a proper use of 
public money.79
Yet just because measuring harms is difficult does not mean
that they do not exist, nor that some attempt to measure them
should not be made.
Recent trends in drug policy
As the culture of drug use changes, and as society’s attitudes to
drugs change, so drug policy needs to evolve. This section
identifies three trends in the formation of drug control policy in
the UK and globally. They include:
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· increasing liberalisation in the USA, Latin America, Europe and
Australasia.
· increasing controversy around drug harms and scheduling and
classifications
· the blurring distinction between alcohol and cigarettes, and
illicit substances
These trends, some of which were discussed in the previous
chapter in relation to the rise of ‘legal highs’, provide the context
for considering drug control policy in the twenty-first century
and the challenge of new psychoactive substances.
Increasing policy liberalisation
Initiated with a strong emphasis on prohibition, drug policy in
some countries has steadily shifted towards ‘harm reduction’ and
treatment in addition to, or as an alternative to, criminal
enforcement. This shift has been underpinned by changes in
public opinion, particularly with respect to cannabis. Figure 1
shows Gallup polls carried out in the USA on the legalisation of
marijuana.80
In the UK, the British Social Attitudes Survey shows that
between 1983, when three-quarters of respondents were against
legalising cannabis and only about a tenth were in favour, and
2001 there was increasing support for cannabis being legalised.
Indeed in 2001 the proportion in favour was roughly the same as
the proportion against; just over two-fifths of respondents in
both cases. However, the 2007 survey showed some reversal of
this liberal trend with just over a half against legalisation and
only a quarter supporting it.81
Policy liberalisation in Europe
Although there is some evidence that public opinion has moved
in the direction of relaxing legislation, at least for some drugs,
changing policy still requires a committed reforming government
to expend political capital in the face of a likely media backlash.
This may be particularly true in the UK. Elsewhere in Europe,
governments have taken steps towards liberalisation.
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Source: Gallup, ‘New Highs of 46 per cent of Americans support
legalizing marijuana’
Despite all European countries being signatories to the UN
conventions on illicit drugs, there is a significant amount of
variation in the way this is translated into drug policy.82 These
differences mainly consist of punishments for charges for
possession of different drugs, but also include policy more
generally relating to cannabis. In Europe, possession of drugs for
personal use is not a criminal offence in Spain, Portugal and
Italy. Perhaps surprisingly, despite the well-known coffee shops
in Amsterdam where cannabis has been readily available since
1976, the Netherlands has not decriminalised cannabis or other
drugs; it has simply chosen not to enforce their laws in the coffee
shops. The same is true in Germany, where personal possession
remains an offence but policy and judicial guidelines recommend
against punishment for these offences. The first European
country to decriminalise personal possession for all drugs was
Portugal (box 5).
Box 5 The Portuguese approach
Much has been made about the Portuguese experience by
experts and those in the media who advocate reform of UK
drug laws. In 2001, Portugal abolished legal penalties for the
personal possession of drugs, including marijuana, cocaine
and heroin, and replaced arrest and incarceration with the
offer of treatment. These changes were based on the premise
that incarceration is more expensive than treatment and that
there are social and economic reasons why treatment should be
the first option and imprisonment a last resort.83
Drug policy debates in general have been predicated on
the assumption that liberalisation (in the form of de-penalisation
and/or decriminalisation) will lead to higher rates of drug use
and greater harms to society. According to Professor Alex
Stevens of Kent University, ‘the example of Portugal seriously
challenges this argument’.84 While it is difficult to extrapolate
from the experience of one country, evidence from an indepen-
dent study found that five years after personal possession was
decriminalised, illegal drug use among teens in Portugal
declined and rates of new HIV infections caused by sharing of
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dirty needles dropped. Moreover, the number of people seeking
treatment for drug addiction more than doubled.85
One of the difficulties in seeking conclusions from the
changes introduced in Portugal is being able to distinguish
changes that would have occurred anyway from those caused
by the legislative change. In their recent study Hughes and
Stevens compare the experience in Portugal with neighbouring
countries and conclude,
the reduction in problematic drug users and reduction in burden
of drug offenders on the criminal justice system were in direct
contrast to those trends observed in neighbouring Spain and
Italy. Moreover, there are no signs of mass expansion of the drug
market in Portugal. This is in contrast with apparent market
expansions in neighbouring Spain.86
As a result of these policy changes, Portugal is one of the
few European countries to have an integrated legislative and
regulatory approach to drugs and alcohol.
In the UK, the introduction of cannabis warnings and
fixed penalty notices following the reclassification of cannabis
back to class B reflected an attempt to reduce the potential
unintended harm associated with criminalisation of young
cannabis users. This followed a long tradition of police
expediency in using police cautions rather than automatic arrest
and prosecution. However, the major increase in recent years in
the number of drug offences recorded, which is largely
accounted for by cannabis possession offences, suggests that an
unintended consequence of this policy is that it has created a
perverse incentive to give and formally record warnings that
might otherwise have been dealt with informally.87
Liberalisation in Australia, the USA and South America
Outside Europe there has been a range of initiatives that soften
or ameliorate the impact of drug laws, particularly for personal
possession. In Australia the penalties in different states vary, but
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in most cases the possession for personal use of cannabis,
including some plants, is not a criminal offence, but one for
which fines can be imposed.
In the USA, the medical use of cannabis has grown
significantly and is now legally approved in 15 states as well as
the District of Columbia.88 While there have been attempts in
some states, for example Montana, to repeal these laws there has
also been the growth and increasing professionalisation of a
budding industry in states like California and Colorado.89 A
recent attempt to effectively legalise the recreational use of
cannabis in California was only narrowly defeated in a referen-
dum, and had attracted a wide range of professional investors.
There have even been statements of support among the most
conservative commentators and politicians in the USA, including
Pat Robertson and Sarah Palin, for relaxing enforcement of laws
against personal use of cannabis.90
A number of South American countries have also recently
sought to decriminalise some drug use (primarily cannabis) in
order to reduce the impact of illegal drug production and
distribution in their countries.91 In August 2009, the Argentine
Supreme Court declared that it was ‘unconstitutional’ to
prosecute citizens for having drugs for their personal use,
asserting that ‘adults should be free to make lifestyle decisions
without the intervention of the state’, though it stopped short of
advocating complete decriminalisation.92 In the same month,
Mexico enacted a law decriminalising possession of small
amounts of drugs, including cocaine and heroin in an attempt to
enable police to focus on major criminals in the drug trade,
rather than dealing with petty cases. Those found in possession
of the equivalent of four joints of marijuana, or four lines of
cocaine, will no longer be viewed as criminals. Instead, they will
be encouraged to seek government-funded drug treatment,
which will be compulsory if users are caught a third time.93
Mexico and Brazil are among other Latin American
countries that are beginning to consider a recasting of drug
policies. In the past few years, high ranking former officials,
including Brazil’s former president, Fernando Henrique
Cardoso, and a Brazilian judge, Maria Lucia Karam, have come
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out against the war on drug policy as being counterproductive.94
More recently, President Calderon of Mexico publicly
acknowledged the need to have a debate about the pros and cons
or enforcement versus legalisation and regulation.95 A recent
briefing from the International Centre for Human Rights and
Drug Policy and the International Harm Reduction Association
argues that changes in a number of South American countries in
favour of decriminalisation for personal possession of drugs are
indeed consistent with international drug treaties.96
Harms and the classification system
While an international debate about drug policy continues, the
UK classification system in particular has come under criticism
in the past ten years as the result of a number of decisions.
Charles Clarke when Home Secretary promised a review of the
drug classification system in 2005 but his successor, Dr John
Reid, did not follow through with this. The farrago over the
reclassification of cannabis, a somewhat modest change in reality,
brought untold opprobrium on the heads of many politicians.
Both of these decisions generated criticism, revealing the
fractiousness of debates around drugs. Other criticism has
stemmed from decisions to classify new drugs, including
ketamine, GHB, and steroids (all class C) as well as magic
mushrooms (now all class A).
Many argue that the scientific basis of classification is
undermined by combining harmful drugs like crack cocaine and
heroin with less harmful substances like ecstasy or magic mush-
rooms in class A. It has also been argued that the complete
exclusion of alcohol and tobacco from classification is not only
analytically problematic, but may also send the wrong message
and amounts to a form of ‘separate but equal’ in harm policy.97
Critics argue that at its worse the classification of drugs has
become a political tool, rather than the expression of evidence 
of harm.
Professor David Nutt, formerly chair of the ACMD, and
other experts recently published a review of harms caused by
different drugs as assessed by experts. The process assessed
Drug control and the policy response
physical, psychological and social harm to users; and harm to
others, mostly social but including physical and psychological.
The results, shown in figure 2, reinforce the critique of the
current classification scheme since several class A drugs are
among those with the lowest levels of harm. It also suggests that
alcohol is the most harmful of all the psychoactive substances
considered, while tobacco ranks sixth, making it more harmful
than cannabis, mephedrone and ecstasy. It should be noted,
though, that a number of concerns have been raised about the
methodology used for this process.
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The blurring distinction between alcohol, tobacco and illicit
substances
One of the key critiques of a number of experts is that extremely
harmful drugs like alcohol and tobacco are not regulated
through the Misuse of Drugs Act (MDA). Instead, because of
cultural and historical precedent they are controlled through a
series of consumer protection, licensing and taxation measures,
with varying degrees of impacts. Each year, alcohol misuse for all
ages costs the NHS around £2.7 billion, but the wider cost to
society including crime and disorder, social and family break-
down and sickness absence is estimated at closer to £25.1
billion.99 There are also high social costs in the UK for smoking,
with the NHS spending approximately £2.7 billion a year
treating diseases related to smoking.100 However, unlike illicit
substances, tobacco and alcohol generate substantial levels of
revenue for the Treasury because they are regulated outside the
MDA. For example, in 2009/10, the Treasury earned £8.8 billion
from taxes on tobacco.101
Some suggest that this has led to confusing public health
messages, for example, suggesting that alcohol and tobacco are
not as harmful as illicit substances, or that messages about the
harm of illicit substances are dismissed as fear-mongering by the
government. There has been increasing attention to
strengthening regulation around the sale of alcohol and tobacco:
for example, the Coalition Government is exploring the idea of
raising the price of alcohol per unit to discourage binge
drinking. More recently, it was announced that the Government
would seek to ban the display of tobacco products in retail shops
and is considering requirements for plain packaging for all
tobacco products.102
As the 2010 EMCDDA annual report argues, there are a
number of arguments that suggest that public health requires a
comprehensive approach to illicit and licit substances that are
potentially harmful and open to misuse.103 Perhaps the most
important reason is that the use of licit and illicit substances
tends to take place among the same population, and possibly in
the same settings. From the perspective of those working in
public health responding to problems with misuse and addiction,
a comprehensive approach is better suited to reality. This has
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been recognised by the most recent 2010 UK drug strategy,
which states that ‘severe alcohol dependence raises similar issues
[to illicit drug misuse] and that treatment providers are often one
and the same’.104 The new body Public Health England will have
a remit to bring together traditional public health efforts (eg
diet, immunisation) with drugs and alcohol treatment services.
However, the drug strategy also recognises that alcohol plays an
‘important part in the cultural life of this country’, and has an
economic contribution ‘with large numbers employed in
production, retail and the hospitality industry’. It notes that
‘pubs, bars and clubs contribute to community and family life
and also generate valuable revenue to the economy’, but points
out that ‘alcohol is a regulated product’.
Legislating against ‘legal highs’: experiences abroad
At present there exists a variety of international responses to
‘legal highs’. Where drug laws are used to control use and supply
there are significant differences between countries. Outside drug
laws are control options that restrict sale, with or without
medical supervision, largely through consumer protection or
trading standards type legislation.
Internationally, there have been different approaches to
controlling ‘legal highs’ thus far, including:
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· an analogue or generic approach
· medicines legislation
· trading standards or consumer protection (‘restricted sales’)
· temporary bans or emergency legislation
Analogue legislation
An analogue approach entails banning or controlling all
substances within a particular chemical group. The US Federal
Analog Act enacted in 1988 is the most cited example of this type
of approach. It was passed as a means of correcting the slow
process needed to schedule potentially harmful substances.
Before this Act the Drug Enforcement Agency had to legislate for
each chemical or substance separately, which could take months
if not years. The scheduling of ecstasy in the USA entailed a four-
year process.105 The Analog Act allows for the scheduling of a
substance if it is ‘substantially similar in structure’ and has a
‘substantially similar chemical effect’ to a substance that is already
prohibited.106 Because of the vagueness of the language in the
Analog Act, and the tendency for courts to defer to government
interpretation, every substance that has been proposed for sched-
uling under the Analog Act has been approved for prohibition.
According to Reuter, it is unclear whether the Analog Act is part
of the reason ‘legal highs’ have been less of an issue in the USA,
or whether it is the comparative severity of prison sentences for
drug prosecutions that have thus far discouraged entrepreneurial
chemists from aggressively targeting the US market.
There has been little public debate in the UK about
adopting an analogue approach similar to the US model, for
example, although the ACMD is apparently undertaking a
review of different approaches including the analogue approach.
Thus far, the Government has opted for introducing temporary
bans (discussed further below); while in dealing with
mephedrone, it has banned a wide range of cathinone derivatives
at the same time. The minister’s comments in a recent
parliamentary debate about ‘legal highs’ suggest that, although
the UK is developing a broader classification approach that does
not have to deal with specific chemicals individually, it is felt that
the analogue approach would cast the regulatory net too widely.
Banning substances without clear evidence of harm could
forestall the research and development of useful medicines, or
have unintended consequences by driving people towards more
harmful substances.107
Medicines legislation
Medicines legislation provides for control of substances through
medical supervision, or prescription. At the heart of such
regulatory and control processes are strict standards to be
applied to product quality control and knowledge about the
likely benefits and problems of their use through established
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clinical trials. Under medicines legislation, the burden of proof
about safety rests largely with the manufacturer and/or
distributor within a structured regulatory framework. In some
countries, including the Netherlands and Finland, ‘legal highs’
such as mephedrone have been controlled through medicines
legislation.108 Austria has also used medicines legislation to
restrict the sale of Spice without criminalising users.109 There has
thus far been little analysis – at least in the public domain –
about the effectiveness of this approach. In the UK and other
countries, producers and distributors of ‘legal highs’
circumvented medicines legislation by putting a disclaimer on
their products saying ‘not for human consumption’ and
advertising them as ‘plant food’ or ‘bath salts’.
Trading standards and consumer protection (‘restricted sales’)
The experience with BZP in New Zealand presents the richest
and best-documented case of a government struggling with an
array of choices for regulating a new psychoactive substance.110
In 2005 the New Zealand Government’s first regulatory
effort placed BZP in a new schedule within the NZ Misuse of
Drugs Act as a ‘restricted substance’. This prohibited sale to
anyone under 18 and prohibited various promotional activities,
which had been widespread, but aside from these measures the
substance was unregulated.111 In lieu of formal regulation,
voluntary guidelines from an industry association were used but
not thought to be effective. Because of this confusion most
people in New Zealand believed use of BZP was legal, whereas in
fact it was merely not prohibited.112
In 2006 and 2007, New Zealand’s Expert Advisory
Commission on Drugs conducted an intensive review of the
regulatory options for BZP and concluded that the risks to users
were moderate.113 As a result, in April 2008 the New Zealand
Government moved to schedule BZP as class 1 under the Drugs
Misuse Act of 1975, which amounted effectively to full
prohibition. To allow for this shift to prohibition, the New
Zealand Government enacted a six-month transition period in
which purchase, possession and use were not yet prohibited.
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Following this, the New Zealand Law Commission
conducted a review of the control and regulation of new psycho-
active substances and published an issues paper that favoured
regulation rather than prohibition as the default option and
proposed some possible options based on current regulatory
frameworks for other substances.114
Ireland has taken an approach which goes beyond this, but
also still represents a form of trading standards control. The
Criminal Justice (Psychoactive Substances) Act 2010 targets
‘head shops’ in which ‘legal highs’ are often sold. Among a wide
range of provisions on drug use paraphernalia and cultivation
equipment, it makes it a criminal offence to sell or supply for
human consumption substances that may not be specifically
controlled under the Misuse of Drugs Acts but which have
psychoactive effects. It also gives powers to the police and the
courts to intervene quickly to prevent the sale of psychoactive
substances by way of prohibition notices and prohibition orders.
It is too early to assess the impact of this approach.115
Temporary ban and emergency legislation
Another approach adopted for ‘legal highs’ has been the use of
emergency powers to ban a substance – often for a year – to
allow for research into its harms. The USA recently used such
emergency legislation to ban five cannabinoids used in Spice.
The planned temporary ban in the UK is one form of such
emergency legislation. As described by the minister with
responsibility for drugs, James Brokenshire MP, the temporary
ban will only apply to the sale, supply and distribution of
substances, and not to personal possession in order to avoid
‘criminalising users, particularly young people’. The waiver of
possession charges makes it unnecessary for police officers to
have to test drugs in order to determine their chemical make-up.
It is however proposed that they can stop and search people and
seize any substance they suspect is subject to a temporary ban.
From a public health perspective, in light of the rapid
emergence of substances about which little is known, a
temporary ban may prevent the spread of a new drug if it is
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enacted quickly enough. It also ostensibly keeps intact an
approach to drug control based on evidence of harms, rather
than simply basing drug control on an over-application of the
precautionary principle (see below). However, there are a
number of concerns about a temporary ban approach. For
example, some suggest that once a substance is subject to a
temporary ban, there is a strong internal logic and likelihood
that the substance will become permanently controlled. This is in
part due to the complications around prosecuting someone
during the temporary ban period and then having to revisit those
convictions if it was later decided that little harm was posed and
the drug should be unclassified. Another concern is that
unbanning a substance could be seen as suggesting it is
completely safe (rather than of low risk compared to other
psychoactive substances) and this might lead to a rapid increase
in use. There is also the risk that a temporary ban could have the
same effect as an analogue approach in hindering the
development of drugs with medical benefit. For example, one
substance recently banned through emergency powers in the
USA as a synthetic cannabinoid (JWH-133) has been shown in
tests on animals to have ameliorating effects on Alzheimer’s
disease.116
The precautionary principle and ‘legal highs’
As Reuter argues in his report, legislating on ‘legal highs’
represents simply another instance of the government being
forced to make policy in the face of uncertainty.117 In this
instance, the harms of these new substances are generally
unknown, as is the likely growth and evolution in this new
market. The precautionary principle is one approach to policy
making in the face of uncertainty when the action in question
may pose ‘a possible danger to human, animal or plant health’.118
The application of the precautionary principle has been explored
mainly in the context of environmental protection, in which
instance it is often used by advocates of environmental
protection in the face of potentially polluting industries. The
precautionary principle assumes that policy makers are extremely
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risk averse in the face of uncertainty. In applying the
precautionary principle, policy makers assume that the risks of a
certain policy choice are so great (often judged on the basis of a
worst-case scenario) that any benefits of that policy choice are
completely outweighed. In contrast, the New Zealand Law
Commission states its view that ‘in a free and democratic society
full prohibition should be a last resort option when lesser
regulatory restrictions have proved ineffective’.119
The adoption of the precautionary principle may seem
appropriate for legislation around controlling new emerging
psychoactive substances. In this instance, it is used to defend the
current approach to drug control through enforcement and
criminal sanction. While some application of the precautionary
principle may be necessary, there is a risk that prohibiting a
substance can actually increase harms, in which case legislation
becomes potentially counterproductive. For example, pro-
hibiting a substance that is still highly desired by substantial
sections of society can encourage the involvement of organised
criminals who are willing to take the risk of legal sanctions in
order to reap the monetary reward of serving that demand. It can
also influence quality control and assurances, the absence of
which increases the harmful impact on individual users on
average. In addition, it makes gathering data on the drug and its
use much more difficult, which impedes the provision of
prevention and harm reduction programmes as well as effective
policy development and enforcement.
The decision to prohibit a new psychoactive substance,
argues Reuter, is similar to the decision faced by drug regulatory
agencies and pharmaceutical companies in bringing a new
medicine to market. On the one hand, a regulatory agency could
face criticism for delaying a potentially beneficial medicine while
its safety was being assessed. On the other hand, bringing a
medicine to market too soon could see a proliferation of
potentially dangerous and ineffective medicines. Similarly,
banning a new psychoactive substance too early can potentially
make it difficult to gather information on its harms and potential
beneficial uses. Banning it too late – as could arguably be the
case with mephedrone – can allow the drug to proliferate and
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become better established. However, there are two important
characteristics that distinguish the two examples.
First, there are well-established lobbying interests on both
sides of the debate about regulating medicines: pharmaceutical
companies and sometimes patient interest groups on the one
hand, and consumer protection NGOs along with bodies like
NICE on the other. However, there is hardly a substantial user
base of recreational users of psychoactive substances that
commands similar influence. There are of course a number of
people who criticise prohibitionist drug policy, but their
influence on policy has thus far been marginal. Second, and
most importantly, there is a clear medical benefit at issue in the
context of a decision about new medicines. The primary benefit
of new psychoactive substances is the pleasure derived by users,
and there is a further benefit if users are encouraged to use less
harmful substances. According to Reuter,
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emphasizing substitution, that these substances may be less harmful than
those that are already being used, whether legally or illegally, may be a more
promising strategy for persuading the public that there can be gains from
allowing regulation of risky new drugs.120
The discourse around drug control ought to take account
of any possible benefits from use of some psychoactive
substances in moderation, as is recognised in the case of alcohol.
These may include simply pleasure or the excitement of doing
something new, but may also be a way of dealing with problems,
including severe physical and mental health problems121 or
improving confidence or performance. These are generally the
reasons why people take the initial decision to use some drugs.
An oft-mentioned concern for policy makers is to send a message
to young people that use of psychoactive substances is harmful,
but for such messages to be credible they also need to acknow-
ledge the factors that attract young people to the use of these
substances. This lop-sided view of drug control may also hamper
the formulation of effective drug policy.
The recent proposal to create new temporary banning
powers to tackle ‘legal highs’ and the use of Open General
Importation Licensing provisions to stop mephedrone and other
cathinones may be seen as an effort to think laterally. But it is
still predicated on the assumption that banning a substance will
control or deter production, supply and use whereas the last 40
years’ experience suggests this is wholly unrealistic. It also does
not take into account the harms that may arise from enforcement
discussed earlier.
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3 A new approach to a
‘wicked issue’
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As argued in the introduction and chapter 2, drug policy is a
notoriously difficult area in which to have rational and
dispassionate policy debates. There are fundamental conflicts of
value and the stakes involved are perceived to be very high.
Politicians engage with the issue at their peril, and often rely on a
risk averse stance that entails an extension of the precautionary
principle. A not inconsiderable proportion of crime in the UK is
linked to drugs of different kinds and there are regular reports of
young people dying or becoming mentally ill following drug use
(although there may be debate about the extent of causal links
between these events). Despite some shifts in public opinion
noted in the previous chapter, most public opinion polls suggest
more people are in favour than against a tough enforcement
approach to drug use. This is particularly true when polls are
carried out after a high profile ‘overdose’, such as the case with
Leah Betts in 1995. Politicians are thus (perhaps rightly) fearful
of media and political reactions to any appearance of being ‘soft
on drugs’. With so much potential for loss, and little obvious
gain, it is little wonder that there is very little political appetite
for changing drug legislation.
Meanwhile, reformers argue that moralising and
scaremongering among the media have wrongly shaped public
opinion. The result, they argue, is support for a policy that
actually causes harm to many people on top of the harms caused
by drugs themselves. While the prevailing cultural value is that
‘drugs are bad’ and ‘drug users are irresponsible’ it should come
as no surprise that few professionals are willing to make public
statements challenging the current legislation. There are calls for
change, but only from retired leading professionals, whether they
are judges, chief constables122 or medical experts.123 Even an ex-
Home Office minister has called for change, but only when out
of office.124 There appears to be little support from current
professionals for change.
While both drug reformers and drug enforcers argue for
their respective proposals and arguments, there is little actual
data on what is or is not effective, as demonstrated in a recent
comprehensive review of evidence.125
This chapter presents a different approach to drug policy
based on a soft systems methodology and the conceptualisation
of the drugs problem as a ‘wicked issue’. Much of the perceived
current impasse on drug control policy is in large part due to the
polarised nature of the debate. This debate tends to reinforce the
view that there are only two options available to policy makers:
controlling drugs through the Misuse of Drugs Act (MDA) and
criminal enforcement, or decriminalisation. Those on each side
of the debate present their view as offering the only solution to
drugs and drug policy. We argue that this is unhelpful, and that
there is no silver-bullet solution to the drugs problem. However,
there are things that can be done to progress a more informed
analysis of different control options for new substances and make
improvements to the current policy framework that are based on
broad areas of consensus.
Our soft system workshops, described in more detail below,
sought to encourage people to reconsider their perspectives, give
greater recognition to other viewpoints, focus on the goals of
drug control rather than competing means, and find consensus
on ways forward. We did this by structuring the discussions
around outcomes on which there was universal consensus, and
avoiding discussion about whether the use of psychoactive
substances is an inherently bad thing. For example, the first
workshop addressed the question: what is the best approach to
protect young people from the harms of new emerging psychoactive
substances?
Framing the question in this way and focusing on
outcomes, rather than asking whether classifying a substance
through the MDA minimised harms, allowed for a more fruitful
discussion.
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Drugs: a ‘wicked issue’
Drug use in society and drug policy are ‘wicked issues’: social
problems characterised by resistance to resolution over long
periods of time, being fractured by different deeply held values
and by being connected to other similarly complex and
unresolved issues.126
The ‘war on drugs’ was launched in the USA in 1970 and
has been viewed as one important stimulus for the MDA
introduced in the UK in 1971. Yet, despite this rhetoric and
significant increases in expenditure on enforcement, drug use in
the USA and UK has increased until recently while the street
price of most drugs has steadily declined. Numerous
commentators have claimed that if it really were a ‘war’ then
governments have been roundly defeated. This formulation of
the issue is widely contested and few today would argue that a
drug-free world is achievable.
There is significant disagreement about whether drug
policy over the last 50 years has been a complete failure, or 
just the least worst option. While the supply of drugs and 
drugs harms remain persistent, many argue that the levels of
prevalence of use and problematic use could be even worse if
illicit drugs were available in the same way as alcohol and
tobacco.
The disagreements around drug policy have two
contrasting roots, both of which are significant. The first lies in
the fundamental values around drug use. For some, drugs are
‘evil’ and their use has to be prohibited and discouraged as much
as possible. For others, government has no right to interfere with
what citizens ingest for their pleasure. And for pragmatists, the
core value is reducing the various associated harms, both to
individuals and society in general.
The second root of disagreement is about how the world is
understood to be operating, and how drug use fits into the fabric
of modern society. Here the issue is one of causation.
Problematic drug use is often intertwined with a range of other
social issues, including family breakdown, poverty, worklessness
and family history of substance abuse. It is difficult to identify
which of these issues is the cause of the others. For example,
many young people who have problematic drug use come from
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deprived backgrounds; is the source of their problems the drug
use or the deprivation?
Traditional policy making starts from the assumption that
the issue to be addressed can be identified and defined. However
in the face of the type of profound disagreements outlined
above, dispute starts at the definitional stage and continues into
what constitutes evidence, what should be the goals and what
means should be used. What appears to be a ‘solution’ from one
perspective is likely to make matters worse from other
perspectives. Wicked problems do not have simple ‘solutions’,
no matter how much the media and politicians would wish
otherwise. Rather, we argue that a more fruitful way of framing
the issue is to seek ‘improvements’ to policy that are supported
by all stakeholders. One of the fundamental problems with
policy making on ‘wicked issues’ is that a huge amount of time
and energy is spent arguing among stakeholders about which is
the right solution. Focusing on improvements to policy which
are backed by consensus can help contribute to more efficient
and less fractious policy making.
A soft systems approach to drug policy
A key feature of this project was to use a soft systems approach to
explore the different perspectives or world views operating within
the drug policy debates in order to identify areas of consensus.
The soft systems method, pioneered by Peter Checkland in the
1970s,127 emerged from systems engineering in recognition of the
complexity in managerial problems resulting from different
views on what the system was, what its goals should be and what
needed to be done to improve the situation. The process aims to
identify these differences in perspective with the aim of gaining a
bigger picture and thereby generating system improvements that
are not in opposition to any of the existing perspectives. To
achieve this, participants in the process are encouraged to voice
their perspective strongly, but with the aim of being understood,
not with the aim of trying to change other people’s minds.
Each workshop for this project focused on a specific
question, though the aim was not to arrive at a definitive answer
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to the question. Rather the question served to limit the scope of
the debate and provide a vehicle for exploring improvement
options.
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The first workshop considered the question:
What is the best policy approach to protect young people
from emerging new synthetic drugs?
The second considered the question:
What steps can we take to control the availability of new
emerging psychoactive substances?
The participants
Each one day workshop had about a dozen participants.
Participants agreed to participate on the basis of anonymity. For
each workshop, we chose participants carefully in order to try to
ensure that every type of stakeholder in the drugs debate, and
represent a wide range of perspectives.
We aimed to have representatives of all the government
departments and agencies responsible for some aspect of UK
drug policy, including areas of enforcement, health, education,
medicines legislation and trading standards. In addition to these
participants, we sought to have a representative of the police at
both workshops, representatives of different frontline drugs
charities with on-the-ground knowledge, a young person with
experience of drugs, advocates representing the parent or carer
perspective, and expert pharmacologists. We also sought out
individuals and academics with specific knowledge of ‘legal
highs’ and new psychoactive substances. Crucially, we also
invited two well-known individuals in the drug policy debate
who represented the more extreme views on drug policy: each
workshop had both a committed and passionate enforcer and
reformer.
The process
The systems workshops began by participants being invited to
draw a ‘rich picture’ of how they perceived the issue. Using
images in this way enables each person to focus on what exactly
they wish to communicate, and to give expression to emotions by
their choice of images and colour. Then each person introduced
themselves to the group, including their job title and role, and
briefly described the elements of their picture. The picture and
short debate that followed gave rise to a number of issues that
were captured on flipcharts by the workshop facilitator. Once all
the pictures had been presented, the group debated the topics
that seemed most significant, either because they generated most
debate or because they recurred a few times. As these discussions
proceeded further, issues were captured on flipcharts after which
they were grouped by issues into themes.
The groups then chose to work on one of the general
themes that had emerged from their discussions by defining an
ideal system that, if it existed, would address the theme. For
example, in the first workshop one of the themes that emerged
was providing information to young people and the ideal system
was defined as:
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A system to enable young people to make informed and responsible choices
regarding substance use before they risk becoming regular users, in order to
enable young people to realise their full potential as adults, by providing
accurate, accessible and relevant information, combined with education
and skills, to both young people, parents and communities while recognising
that different groups will require the information presented differently.
Arriving at the definition of an ideal system requires debate
about what exactly the system is seeking to achieve (its purpose),
why this is important and how it is to achieve its purpose. This is
an iterative process in the sense that the formulation of a
definition usually illuminates something that has, to date, been
overlooked or perhaps simplified. Once an adequate definition is
achieved the group then considers the sequence of activities that
would be required for this ideal system to fulfil its purpose. In
the example given above, key activities would include gathering
and assembling relevant information, assessing its accuracy and
relevance, identifying the key audiences, and for each audience
devising appropriate messages, media and methods of
transmission.
Once the set of activities for the ideal system have been
assembled they are then compared with what is happening in the
real world. This then leads to a debate about what steps could be
taken to improve the existing system in the direction of the ideal.
In the example illustrated above, it was agreed that the most
important step was the collection and collation of accurate
information on new psychoactive substances since without the
completion of this activity no other part of the system could
operate effectively. By focusing on concrete purposes and using
the rigour of systemic thinking, the group could come to an
agreement about an improvement without becoming bogged
down in their different perspectives.
Workshop questionnaire
One of the aims of the workshops was to enable the participants
to enlarge their own view of the issues. It is normal for
participants in this type of workshop to be influenced by
increasing their understanding of each other’s perspective. In
order to explore whether such changes took place, participants
were invited to complete a short questionnaire (see Appendix II)
before and after the workshop. The results confirmed the
expectation that people did not move their positions much,
presumably because they had previously understood each others’
positions. However there were some changes and these are
summarised below:
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· In both workshops, there were slight shifts from positions of
certainty to uncertainty: participants became less certain of their
views. General comments also reflect that they had broadened
their perspectives and considered wider options for control.
· Of all the questions asked in the survey, both workshop groups
were most unsure about whether the temporary ban will be the
most effective approach, suggesting they were unclear about the
implications of such a policy.
· Both groups agreed that the emergence of new substances
requires a new approach to drug control, and that providing
education is an essential prerequisite for deterring use.
Different perspectives
As mentioned, a key reason for using the systems workshops was
to identify the different perspectives that were operating within
the drug policy debate. The workshops succeeded in this respect
and a number of the different perspectives are summarised
below. The aim of this summary is not to pigeonhole people, but
to provide composites designed to convey a flavour of the
differences that emerged. It is important to recognise the
variation within categories of participants so individual
participant’s views often differ from those in a particular
category. For example, not all members of the police will concur
with the description attributed to the police below. It should also
be recognised that individual participants are quite likely to hold
conflicting views and beliefs about the issues. Nevertheless, for
developing a bigger picture of the drug policy domain the
following summaries capture something of the extent and nature
of the different perspectives to be found.
The police’s perspective
Box 6 The police’s perspective
The young people the police come into contact with who are in
trouble with drugs are in a high-risk group from broken or
chaotic homes. It does not help to criminalise them, or other
young people, for their involvement with using drugs:
How people choose to get off their heads is really none of
our business – provided that they do not engage in risky
or illegal activities (other than possessing illegal drugs).
The risky activities are things such as driving, getting
into fights and so on. Our job is to catch the villains who are
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making a lot of money by importing, distributing and selling
drugs.
The police saw the paradox posed by the current
prohibition system quite clearly. They wanted drugs to be illegal
so that they could catch the villains who make money from
drugs, while at the same time not wanting to wreck young
people’s careers by giving them a criminal record.
Reformers’ perspective
Box 7 Reformers’ perspective
Reformers think the current system simply does not work.
Drugs are cheaper and more widely available than ever before;
this after almost 40 years of control under the MDA.
Thousands of young people have their lives wrecked by being
given a criminal record as a result of recreational drug use.
Banning a substance does not have much impact on its
availability, but it does make drug use more hazardous due to
lower purity, unknown dosage and unknown contaminants. A
regulated system is both possible and preferable and, as the
example of cigarette smoking demonstrates, need not lead to
uncontrolled use.
Reformers tend to be advocates working for charities
and/or campaigning organisations with well-known views
on drug policy. Reformers often do not fully address the
fact that making something legal and regulated might lead
to an increase in its use, which could lead to an increase in
harms associated with addiction.
Drug workers’ perspective
Box 8 Drug workers’ perspective
Officialdom has no idea what’s happening on the street. The
problem with new substances is the lack of accurate and
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reliable information. No one, not the young people using them,
nor the drug workers trying to give advice about them, nor the
doctors in A&E units treating users, knows enough about these
substances, and there seems to be a continual supply of new
ones. The lack of information is about dosage, toxicity, side
effects and issues associated with mixing different drugs. There
is a growing body of data available among young people and
drug workers, but no one is collecting and collating this, and it
could be the basis for giving advice. Messages about extreme
dangers of drugs are negated by peer experience, so the whole
drug advice and education system is brought into disrepute.
The young people who get into trouble with drugs are usually
‘at risk’ for other reasons and fall foul of mixing different drugs
(including alcohol).
Frontline charity workers tended to have a very pragmatic
perspective based on aiming to reduce harm at the street level.
Legality is seen as less of an issue than accurate information. The
best advice given to youngsters is, ‘If you are having fun that’s
OK, but if you are using any drugs to get out of it then stop, you
are overdoing it.’
Civil servants’ perspective
Box 9 Civil servants’ perspective
Civil servants are involved in delivering a harm reduction
agenda while perceiving that radical changes to drug
legislation are unlikely any time soon, so they accept the
constraints of the existing system. This leaves them with a
dilemma because they recognise the drawbacks of the current
policy, but are not convinced that decriminalisation is the
answer. They recognise different groups of users (teenagers,
clubbers, old hippies) but these differences are not represented
in policies or campaigns. They are puzzled by many aspects of
drug use including the changes in fashion that determine drugs
of choice and the steady decline of teenage use of both drugs
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and alcohol since 2001. They recognise that the young people at
greatest risk are those from disadvantaged backgrounds, and
these can be targeted independently of drug use. For this group
the most effective assistance is helping them make less risky
decisions in all aspects of life.
Civil servants tended to adopt a very intellectual approach,
largely because they do not see it as part of their role to challenge
the moral or value judgements involved. They are also aware of
potential paradoxes, eg demands for classification of substances
on the basis of harms quickly before any evidence of harms can
be obtained, which then makes obtaining such evidence
extremely difficult.
Professionals’ perspective
Box 10 Professionals’ perspective
Professionals (pharmacologists, academics, clinicians) believe
the MDA is no longer fit for purpose. The classification system
is crude and not related to harm: and does not appear to have
any effect on users’ decisions. Banning substances changes the
sellers, not the users, and means that what is used might be less
pure and the users less certain of what they are ingesting. The
mephedrone issue brought the Advisory Council on the Misuse
of Drugs (ACMD) into disrepute and illustrated that policy
was driven more by the media than by scientific evidence. They
recognise that there is a moral judgement driving prohibition,
and that this is a valid role of government. However they also
see that pursuing a harm reduction agenda might well lead to
some substances being regulated rather than banned. They are
also concerned by the anomalies in the current system (eg
around poppers, GBL, nitrous oxide).
This is quite similar to the civil servants’ perspective, but
less bound by politics, as well as the reformers’ perspective. It is
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an open perspective that requires clear evidence to determine the
way forward that would actually reduce harms.
Enforcers’ perspective
Box 11 Enforcers’ perspective
Enforcers believe that any relaxation in the legal position will
lead to a dramatic increase in use of drugs, with a concomitant
increase in the harms due to addiction, mental illness,
overdoses and other accidents. Drugs are bad and we have to
do all that we can to stop young (and older) people using them.
We have to be much tougher using border controls to prevent
the importation of drugs of all kinds. We have to be tougher on
the criminals who import and distribute drugs and we have to
combat the pervasive pro-drug culture in the UK. The sake of
our children’s future depends on maintaining an approach to
drugs backed by the threat of criminal sanction to send the
right message of deterrence.
At the workshop this perspective was presented as being
entirely based on a desire for harm reduction. Nevertheless the
implicit value judgements that drugs are bad, that being
intoxicated is not good and that the moral fibre of our culture is
at risk was always visible beneath the surface. This appeared to
be the most ‘closed’ perspective at the workshop; there was very
little scope for any shift.
Young people’s perspective
The significant perspective not represented at either workshop
was that of young people. The first workshop included a young
person below the age of 25 years old who had previously had
problems with drugs and was working as a peer drug mentor for
a local charity.
At the workshop it was recognised that there were several
sub-groups of young people of relevance, characterised during
the workshops as:
A new approach to a ‘wicked issue’
A Young people who do not use drugs, or have tried drugs a
couple of times but ultimately do not use. According to available
surveys, this applies to the majority of young people.
Participants at the first workshop raised the question of why the
majority did not use drugs. Was it as a result of personal
inclination, lack of opportunity or because drugs were illegal?
B Pupils still at school who use drugs occasionally. The interesting
question that arose regarding this group was why the
consumption of all types of drugs and alcohol in this group has
steadily declined since 2001.
C Clubbers and other young adults in the age range 18–30 who
used drugs recreationally as part of a dance culture in which
drugs enhance the experience and facilitate the ‘all night’
participation that is a feature of this scene. This is the group that
adopted mephedrone enthusiastically in 2008/09 and towards
whom the ‘legal highs’ marketing is targeted.
D Young people of any age for whom drug use becomes
problematic. This is a small proportion of the total number of
young people using drugs. It was also recognised that in most
cases drug use was a symptom of more general problems for this
group who were at risk for other reasons.
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In order to ensure representation of young people in the
research, we conducted a separate focus group with eight young
people between the ages of 17 and 25. The focus group was
arranged with help from the Foyer Federation, and included
young people who were living in one of their supported
accommodation centres. While young people in Foyer
Federation housing often come from chaotic households, and
would fall into category D above, those who participated in this
focus group appeared to fall into group A or B of those outlined
above.
Box 12 A young person’s perspective on drugs
Alcohol and tobacco are just as harmful as drugs like cannabis
and ecstasy, though ultimately it’s very difficult to say which is
more harmful (there was little consensus on the relative harms
among the group of young people we spoke to). They suggested
people use drugs for a range of reasons, but mainly through
curiosity, boredom, because everyone else is doing it, the media,
and popular music and culture. Legality of a substance doesn’t
matter as much as the effect. Young people will take things that
make them feel good, and try things that their friends
recommend. For some, even, the illegality of something makes
it more cool and more desirable:
They don’t really care whether it’s legal or not… if people
give them something they’re like ‘what’s this’, not ‘is this
legal’, they don’t care if it’s legal. If it gives them a buzz,
the higher they feel, the better they think it is. They don’t
care if it’s legal or not. Most of the time, if it’s with the
people they trust, they don’t care if it’s legal anyway.
The media plays a huge role, with lots of young people
using drugs because they see other people (singers, rappers)
doing it.
Most of the young people in the focus group had heard of
mephedrone but were not necessarily familiar with the term
‘legal highs’. Their knowledge of mephedrone mainly came
through the media, though a few had friends who used it; no one
at the focus group admitted to trying mephedrone, or other
drugs. Although they described friends getting it from other
friends, motivations for using mephedrone were thought to be
curiosity, legality (‘they don’t get done for it if they get caught’)
and availability. One participant noted their friends had tried
Spice, mainly because it was legal, but didn’t like the effect so
went back to smoking cannabis. In general, the young people
were very aware of the harms of drugs, tobacco and alcohol.
There was lively debate about whether alcohol, cannabis or
tobacco was more harmful, but almost all the participants
thought that ecstasy and mephedrone were very harmful.
Opinions were again divided over whether drugs should be
controlled: many felt that the harms caused by alcohol were the
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result of its easy accessibility. Nevertheless, most felt that
legalising cannabis ‘wouldn’t make much of a difference’ because
it was already widely available. No one thought that all drugs
should be legalised. Interestingly, one participant spoke about
being surrounded by drugs, including from his parents, but ‘got
a thrill’ from saying no:
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But I’ve chilled with these people my entire life, and I’ve never taken these
things. My dad is the biggest smoker you’ll ever know. All my friends. I’m
always in the circle. If I’m going to die it’ll be of passive smoking, because I
take it every day, I’m always around him. He’s like do you want some, and
I’m like no, I’m alright. My thrill is saying no. I get a thrill out of it – like
yeah, I can say no. That’s why I’m so independent today.
One of the surprising features of both workshops was that
the debates between the participants were extremely constructive
with a great deal of acknowledgement involved in the exchanges.
This was in sharp contrast to the way drug issues are presented in
the media. All the participants had considerable experience of
working with and around drug policy and the discussions were
rich in ideas and challenges, some of which are included in the
description of perspectives above. The next two chapters
summarise the issues on which the participants in each workshop
were able to form a consensus. This should be instructive to
policy makers in seeking to make improvements to drug policy
that would enjoy wider support.

4 What is the best
approach to protect
young people from
emerging new synthetic
drugs?
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· a civil servant (enforcement)
· a civil servant (health)
· a civil servant (young people)
· a police officer
· a police officer
· a director of medical research, leading charity
· a parent (affected by their child’s use of a ‘legal high’)
· a director of a leading reformer charity
· a pharmacologist
· a frontline worker, charity focusing on the club scene
· a frontline worker, London borough charity
· a peer support worker, London borough charity
Why do young people use drugs?
Participants in the first workshop agreed that most young people
do not use drugs. Those that do, do so for a variety of reasons.
For some it is fun, curiosity, exploration, and there are some who
It is important to emphasise that our focus was explicitly on new
compounds and not on the use of established drugs. Indeed one
of the implicit conclusions that emerged from both workshops
was that it was important to differentiate policies appropriate to
different drugs and different groups of users. A significant source
of unintended harm and confusion arises as a result of the
attempt to lump all drugs and all users into the same category.
This is an anonymised list of the participants who attended
the first workshop:
just like the effects. Others may explore drugs but then decide
they do not like the effects. Teenage years are characterised by
boundary testing, experimentation, rebelling and trying
something just because it is new. Some use drugs as a way to
escape stresses of family, work or the boredom of day-to-day life.
Only a small minority of young people who try drugs end up
running into difficulties. This minority are often but not always
from disadvantaged backgrounds or otherwise in a high-risk
group.
The participants with experience of working with young
people who run into trouble with drugs agreed that for many of
them the use of drugs was a symptom of other problems, not a
cause. The same young people were likely to be in trouble with
anti-social behaviour, crime and promiscuous sex. Members of
this group were not hard to identify and the workshop partici-
pants, particularly civil servants and frontline workers, felt that
the best approach was to devise ways of enabling them to make
less risky decisions. This could be done, in part, through
education and providing parental and community support
services. Laws about drugs were going to be as ineffective as laws
about sex with this group, and ‘legal highs’ posed simply
another risky opportunity.
Participants agreed that there were many influences and
environmental factors acting on young people that may have an
effect on drug use and experimentation, including family
pressures and attitudes to drug taking, community cultural
norms, risk-taking behaviour, youth culture, music and the
media (‘social norms’). Personality traits including potential
genetic influences are also significant, including being prone to
thrill seeking, anxiety and depression. All participants argued
that identifying these young people and working with them to
address those underlying factors that can be changed early on
(which could happen at school) could reduce drug use later.
However, although a range of factors was identified as
likely to be significant, there was still no proven evidence known
to participants explaining why drug and alcohol use among
school pupils has been steadily declining for the last decade.128
There is clearly scope for improving our understanding and
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using this to provide guidance and advice to those groups at
greatest risk. One proposed way forward is to analyse why some
young people do not use drugs (particularly those in a high-risk
group), rather than to ask why those who do use them do so.
Box 13 Positive drug experiences
It is estimated that over one-third of 16–59-year-olds in
England and Wales have used an illicit drug at some point in
their life. This does not of course make it right or beneficial.
But many will have got some pleasure, at least initially, and
sometimes over a longer period.
There are a number of benefits that people derive from
psychoactive substances. The first area is that of mood
enhancement, which is said to improve openness, reduce
inhibitions and increase social bonding. This is the basis of the
‘having fun’ aspect of drug use and is very similar to the
benefits obtained from the social use of alcohol. The second area
of benefit is the reported increase in creativity experienced by
many people using drugs such as cannabis, hallucinogens and
cocaine. This use of drugs has a long history in human culture
and accounts for the popularity of many drugs with artists,
musicians, poets and people working in the creative
industries.129
The third area of reported positive experience arises as a
result of enhanced sensory perception and experience,
particularly associated with listening to music, watching films
and sexual experiences. The fourth domain was promoted as
the basis of the cultural revolution in the 1960s and is the
reported expansion of consciousness or awareness associated
with many, but not all, illicit drugs. Many young people report
highly significant spiritual and psychological experiences with
drugs, events that can often be interpreted as shaping their lives
for the better. The famous ‘Good Friday experiment’ carried
out at Harvard in 1962 has recently been repeated as a double-
blind clinical trial to test the effect of psilocybin with 36
volunteers who had never used hallucinogenic drugs. The
authors concluded, ‘The most striking finding… is that a large
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proportion of volunteers [67 per cent] rated their “psilocybin
experience” as among the most personally meaningful and
spiritually significant of their lives’.130
Many of the reported positive effects of drug use appear
to depend on the relaxation of perceptual, cognitive and
sensory filters that normally condition experience. However,
those relaxations can also be the source of difficulties for
vulnerable groups, since a similar process can result in the
psyche being overwhelmed by paranoia and psychoses. Finally,
the fifth domain of positive experience for drugs is the role the
play in facilitating the all-night dancing which characterises
the club and rave culture that emerged in the 1990s and
continues to this day in the UK and across Europe.
For any drug control policy to be more effective at
controlling new substances it will, at some point, have to
acknowledge this reality.
What is the aim of drug policy for young people?
There was some debate in the workshop about what the goal
should be for drug policy for young people. Participants felt that
there was an expectation among parents and the media that laws
that prohibit the distribution and use of drugs can invariably
protect young people. Nearly all of the participants agreed that it
was unrealistic to aim to prevent all drug use among young
people, and yet this aim is the source of much of the demand for
tougher legislation and enforcement. While some argued this was
not even desirable, the majority agreed that while it may be
desirable it was not a feasible aim. A recent estimate indicates
that customs and the police intercept about 1 per cent of heroin
and crack cocaine entering the UK, an indication of the
impossibility of effectively enforcing drug laws.131 With over a
third of the adult population reportedly having used an illicit
drug at least once, including over 20 per cent of school pupils in
the UK population, drug control legislation apparently does not
prevent use of illicit substances.
Nevertheless the need for protection, especially for young
people, was clearly recognised throughout the workshop
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debates. Participants agreed that in an ideal system, the aim of
drug policy would be to enable young people to make informed and
responsible choices about substance use before they risk becoming regular
drug users in order to enable them to realise their full potential as adults.
This required:
85
· providing accurate, accessible and relevant information,
combined with education and development of skills, to young
people, parents and communities
· targeting the information, education and skill development
particularly to at risk groups (recognising that different groups
require the material to be presented differently)
· providing mentoring services to offer extra one-to-one support
The importance of information on new psychoactive
substances
Participants agreed that the best foundation for reducing harms
to young people was to provide accurate, relevant and helpful
information and advice. Information about the nature and
effects of new substances was considered to be crucial for
everyone involved in the drugs field for the following purposes:
· effective drug education to enable young people to make
informed decisions about whether or not to use drugs
· development of strategies to encourage young people who
choose to use drugs despite knowledge of dangers to make less
risky choices
· treatment of those who have problems as a result of drug use
· understanding the extent and nature of use and making
decisions on appropriate control measures
· enforcement of relevant controls
In this context it was also recognised that at the very least
there were three separate groups to be targeted:
· youngsters who have not yet tried any drugs; the aim would be
to provide information to enable these young people to make an
informed decision about the health and legal risks weighed
against the potential benefits of taking drugs
· those who had already used drugs and would continue to do so;
the focus would be to provide this group with information on
how to use drugs safely and the warning signs of imminent
trouble
· those who were already experiencing difficulties in the form 
of dependency, paranoia or excessive use; the focus would 
be on providing information on self-help and treatment 
options
What is the best approach to protect young people?
It was recognised that providing information to these
different target groups could pose problems, especially when
giving messages about avoiding use to one group and how to use
drugs safely to another group.
There was a serious problem with assembling reliable
information on new psychoactive compounds – effects, dosage
and hazards – especially when combined with other intoxicants.
Some participants felt that our knowledge about new substances
becoming available is very poor and that controlling a substance
under the Misuse of Drugs Act (MDA) makes collection of the
necessary information more difficult. This was seen by the
participants as one of the many unintended effects of
classification and scheduling.
Legality and classification: unintended consequences
Workshop participants recognised that there were a number of
potentially important unintended harms that resulted from
current drug legislation. Participants, particularly the police, saw
one of the biggest harms of classification as the criminalisation of
large numbers of young people. In a system as complex and
varied as the supply and use of hundreds of different
psychoactive compounds, there will inevitably be unintended
consequences of any control regime. Although it is impossible to
devise a perfect system, most unintended consequences could be
anticipated, and they should be considered in framing new
regulations for new compounds.
The frequently repeated view that the MDA had passed its
sell-by date was based partly on the poor relationship to levels of
harm,132 and also related to the number of unintended harms it
created. Some participants – particularly reformers – noted that
there has been a steady move toward de-penalising and
decriminalising substances for personal use (see review in
chapter 2) in other countries. Although not explicitly stated at
the workshops, this suggests that the consideration of
unintended harms should be part of the remit of the Advisory
Council on the Misuse of Drugs (ACMD) in considering its
recommendations to government.
It was also felt that drug policy and the classification of
drugs were of little significance to those using drugs (though it
may inhibit some from starting to use them). Legality was felt to
have a greater impact on sellers than buyers: high street shops
and domestic internet outlets were unlikely to persist once a
compound was classified, leaving the only sellers on the streets
and the profits financing organised crime. The issue of legality
was also tied up with the purity of drugs. It was reported that
while new compounds were legally available they were very pure;
once they became illegal then the purity was variable. The loss of
purity and labelling meant that users of the compound were less
able to gauge dosage. Also as one compound was made illegal,
users were likely to switch to another – one that might be more
toxic and on which there may be even less information available
within the user community.
There was general agreement that it was difficult to
establish whether making a drug illegal increased or decreased
the harm to young people. On the one hand it might deter some,
but the illegality may also make it more attractive to others
(some concluding that it must be good if government bans it).
The loss of purity and user information – both arguably
consequences of MDA classification – increased the risks among
those using the drugs. The classification of drugs is currently
unsatisfactory, with some widely used drugs still legal (poppers,
nitrous oxide and GBL).
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Improvements to drug policy to better protect young people
The Coalition Government is committed to looking at new ways
to influence people’s behaviour in order to encourage them to
make less risky choices and act more responsibly. This emphasis
on influencing choices around risky behaviour was in evidence
throughout the workshops we conducted. While legislation can
impact on drug use prevalence, there are a number of issues
relating to drug education and availability of information that
suggest current approaches are not effective at influencing
behaviour. As noted above, influencing less risky behaviour is
especially important for young people who display background
factors that predispose them to greater risk taking.
It was generally agreed that broader intervention initiatives
delivered in schools and communities, such as Strengthening
Families, could have more of an impact on drug use than
interventions that were drug-specific. These broader initiatives
helped to build emotional resilience among young people to
withstand the pressures and influences around drug use that they
are inevitably exposed to. In a recent meta-review of evidence by
a team of international scientists from a variety of fields, it was
argued that family, community and school-based interventions in
the USA that focus on a ‘broad set of mental, emotional, and
behavioural disorders as well as drug use’ have been shown to
have more impact than ‘purely didactic prevention
programmes’.133
Workshop participants agreed that addressing the problem
of a lack of information was the most useful way forward to
improve the protection of young people from new psychoactive
substances.134 Key activities identified by workshop participants
included:
What is the best approach to protect young people?
· creating a framework that allows better information sharing
between frontline workers, users and the government
· providing support for testing facilities in clubs and other venues
where synthetic drug taking is prevalent
Creating a framework for better information sharing
between frontline workers, users and the government
One route identified was to establish ways in which front-line
organisations and charities working with drug users could collate
information and provide it to a coordinating body, possibly the
ACMD. The Coalition Government is planning an early warning
system but it was felt that government and agencies needed to
make better use of the potential data that are and could be made
available (eg the Mixmag surveys), but also initiate more
comprehensive information-gathering initiatives and processes.
Frontline workers felt there was a wealth of information about
new drugs available, through their work and myriad drug user
forums on the internet, pharmacists, A&E and research literature.
However, at present, no systematic framework existed to collect
this information and disseminate it to the Government, the
ACMD, public health and police bodies, other charities or to
young people.
Creating this type of framework (partly envisaged in
government plans) was seen as key to anticipating the arrival of
new compounds, rather than continually playing catch-up. Three
specific ways this could be achieved were identified:
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· searching internet chat rooms where users exchange information
on new substances and their effects
· approaching (largely Chinese) manufacturers of ‘legal highs’ to
enquire what compounds they were researching or preparing
· using the commercially available pharmacological testing
procedures used for assessing new medicinal compounds, 
which would give reasonably accurate data on how the
compound functioned pharmacologically, its likely effects and
toxicity, all essential information in preparing any regulation
strategy
It was also felt that Government and the ACMD needed to
develop a minimum data set of information, and that approaches
cannot be substance-specific. According to our eminent
pharmacologist participant, a full trial of mephedrone could take
five years, so there is a need to be pragmatic and develop an
approach that can deal with a variety of new and emerging
substances. It was argued that in vitro testing can provide a
rough profile of effects of new substances.
While policy makers and ministers are playing catch-up
they will always be prey to media campaigns and political
pressures at critical junctures demanding action on new
substances. If they can garner better intelligence they may be in
a better position to respond to or be in advance of media and
political concerns. Such approaches combined with
complementary control approaches (along the lines we set out in
chapter 5) could offer novel approaches to control new
substances.
Provide support for testing facilities in clubs and
other venues where synthetic drug taking is prevalent
One of the most significant problems facing enforcement and
drug users alike is growing deception in drug markets.
Mephedrone is being sold as cocaine, BZP is being sold as
mephedrone, and some pills contain a mixture of illicit and licit
substances. This deception about dosage and strength levels
makes it difficult for individuals to make informed decisions
about the risks they would take by consuming an illicit
substance. Providing them with reliable and accurate
information can allow them to make less risky choices (including
to use less or no drugs) and act more safely and responsibly.
Providing financial support for these activities is not necessarily
something that the Government need do. However, as a
principle, funding should not be withdrawn from charities and
organisations that are providing these services.
What is the best approach to protect young people?
5 Steps to control the
availability of new
psychoactive substances
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Although there was clearly some overlap with the question
addressed in the first workshop (about the best approach to
protect young people from emerging new synthetic drugs), the
second workshop focused particularly on the most effective
legislative approach for controlling new potentially harmful
substances and so took a different direction. This included views
about the effectiveness of the current approach of classifying and
scheduling substances according to the Misuse of Drugs Act
(MDA), the creation of a temporary ban classification, and an
exploration of complementary control regimes for responding to
new substances.
The second workshop was attended by the following
stakeholders:
· a civil servant (health)
· an enforcement officer (consumer protection/trading standards)
· a civil servant (health/medicines)
· a police officer
· a police officer
· a former civil servant (enforcement)
· a former civil servant (enforcement advocate)
· a lawyer, reformer charity
· a drug education specialist
· a pharmacologist
· a frontline youth worker, London borough
· an academic, specialising in new psychoactive substances
The global nature of the problem
Participants agreed that the emergence of new psychoactive
substances is a global problem because of the way they are
produced and distributed (in 2011, coming predominantly from
China) and the way information about them is ordered and
shared via the internet. The market for new substances was
driven by the desire for drug taking in the West, and the money
that could be made by producers in supplying this market.
Participants felt that these factors posed a series of new
challenges that existed outside current control mechanisms.
Moreover, these new challenges were added on top of existing
concerns about the current system of control, which was not
perceived to be working well enough, as discussed in chapter 2.
Issues relating to control and regulation of ‘legal
highs’
Much of the discussion focused on different options for
regulation. This included regulation through the Medicines and
Healthcare Products Regulatory Agency and medicines
legislation, or through Trading Standards provisions, which
regulate solvents, tobacco and alcohol among other substances.
Currently, sellers of ‘legal highs’ have circumvented medicines
legislation by advertising psychoactive substances as ‘not for
human consumption’ or for alternative uses. It was also
suggested that, because of the lack of other beneficial medicinal
uses for ‘legal highs’, medicines legislation would not be an
appropriate mechanism of control. The possibility of dual or
multiple use for substances determines the type and extent of
control measures. For example, amyl nitrites (poppers), although
quite frequently used as a stimulant, are not controlled under the
MDA as there are many industrial uses for these chemicals so
banning them would be problematic.
It was felt that a regulatory system that included better
labelling, advice and purity could reduce some harms associated
with new psychoactive substances, though this sentiment was not
shared by all of the workshop participants. Such a system would
also hold the seller or distributor accountable for the
demonstration of public safety (as with foodstuffs and
medicines) providing evidence and warning about potential
harms, rather than placing the burden on the Government to
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determine whether substances are harmful. However, it was felt
that, to be adopted, a control or regulatory system for new
substances needed to demonstrate a clear benefit (not just a
reduction in harm).
Moving forward: options for control
Based on the discussion in this workshop, we concluded that
there are broadly five options available to the Government in
seeking to control the availability and use of new ‘legal highs’.
Participants at the workshop agreed the following:
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· There is a wide range of different pieces of legislation besides the
MDA that could be used for controlling new harmful substances.
· The number of substances now controlled and the multiplicity of
ways in which this is done is confusing and potentially inefficient
and ineffective.
· There are a number of potential benefits to taking a step back
and producing a simplified, overarching control framework, such
as a Harmful Substances Control Act. This framework would
include alcohol, tobacco and solvents, among a range of
potentially harmful substances.
In considering the different options for control it is
important to be clear about the objective of the exercise and 
the criteria that a good or more effective control framework 
must meet. Our research and the workshops we have under-
taken would suggest that a suitable control framework would
aim to:
· provide protection for the public (and especially children and
young people) from potentially dangerous substances
And to be effective it must:
· ensure there are practical and enforceable control mechanisms in
place for the production, supply and distribution of potentially
harmful substances
· ensure those who produce or supply substances outside any
control regime are dealt with in a proportional manner
· meet international obligations under UN drug control
conventions and EU treaties
· be designed to minimise unintended harms resulting from the
application of the regulations
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These factors bear much similarity to those endorsed by the
Police Foundation Independent Inquiry into the MDA.135
But what are the realistic options available to a government
and parliament that wishes to reduce the risk of widespread use
of potentially harmful substances without incurring other
unintended harms from the associated enforcement efforts and
accompanying black markets? Figure 3 below provides a
visualisation of the different forms of control that exist for
psychoactive substances in the UK. We have used these options,
in conjunction with the discussion in the workshop, to identify a
range of possibilities to controlling new psychoactive substances,
from little change to more radical approaches.
Option 1 An ‘as you are’ option
Until there is clear evidence of harms, it could be argued that
there is no reason to place any controls on these new substances.
Any system of controls will take resources to enforce and have
the potential for having a negative impact on users, for example
through criminalisation. The use of the new substance may also
have benefits, for example substituting for something more
harmful, which might be negated by any system of control.
Given that there is an element of fashion involved in recreational
drug use it may be that the drug will have a period of popularity
followed by a natural dwindling in use anyway.
However, there are a number of potential problems with
this approach. First, it may take some time before the harms
from taking a new drug are evident and it may become harder to
control a substance once a market for it has developed than
when it first emerges. A challenge also comes from the
expectations placed on the UK as signatories to various UN
drug control conventions and similarly with EU treaties. Once
there is an international call or agreement to prohibit a substance
or to introduce stricter controls then the UK would be in an
embarrassing position if it were to stand out against such moves.
In addition there may be pressure from the media, concerned
family members and political opponents that ‘something must
be done’ to stop new drugs, whether or not there is compelling
evidence of their harms. In such cases, the momentum to classify
a new or emerging substance under the MDA may become
overwhelming.
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How governments control potentially harmful substances
Medicinal Controls 
(Medicines Act)
Amyl Nitrate
Morphine
Misuse of Drugs Act
Heroin
Cocaine
Cannabis
Figure 3
Licensed/regulated drugs Unregulated sales
Controlled drugs
Consumer protection
and trading standards
Alcohol
Tobacco
Intoxicating 
Substances
Supply Act
Solvents
Option 2 Control under the Misuse of Drugs Act and increase
enforcement
A second option is to control new substances under the MDA
and provide increases in expenditure for enforcement agencies
including the police, customs and the planned National Crime
Agency, to be able to increase their efforts to reduce production,
supply and use. In the foreseeable economic climate, and set
against a planned substantial reduction in expenditure (with
estimates ranging from 6 per cent to 20 per cent) for police
services in 2011/12 and future years, this does not seem a
plausible option. Various estimates have been made of the utility
of extra spending on enforcement activities and there is no hard
evidence that increasing spending would result in a proportion-
ate decrease in supply and availability. There might be more
arrests of criminals and drug seizures, as has happened over the
past 40 years. But the simple economic laws of supply, demand
and prices suggest that, at best, the lid is being kept on the drugs
market.136 It is highly probable that the law of diminishing
returns is already operating and we would see increasing
inefficiencies.
Option 3 Use the current drug control legislation more flexibly
A third option is to take the opportunity to be more flexible
within the current drug control framework. For example,
anabolic steroids are class C drugs to be sold only by
pharmacists with a doctor’s prescription. It is legal to possess or
import steroids as long as they are in the form of a medicinal
product for personal use. But possession or importing with
intent to supply (which includes giving them to friends) is illegal
and could lead to 14 years in prison and an unlimited fine.
Cannabis is a class B drug with a maximum penalty for simple
possession of five years’ imprisonment and an unlimited fine,
like other class B drugs. But for cannabis the police also have the
power to issue warnings and penalty notices with a fine, and are
using them with increasing frequency, if unevenly, across the
country.137 Recent advice from the Association of Chief Police
Officers following the control of the cathinones, including
mephedrone, was that unless there were special circumstances,
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the police should avoid arresting users for simple possession
cases.138
The new temporary control measures will not include
penalties for possession, although police officers will be able to
search people suspected of possessing the drug and seize any
suspect substances (without having to verify that they are the
substance in question). Therefore it is probable that police
resources will be directed more towards intervening in the
production and supply chains rather than the consumption or
user end. If a drug subsequently becomes formally controlled
under the MDA, it is possible that the police may continue with
this approach. On the other hand, there is no guarantee they will.
The Government has recently turned also to the use of
other powers to complement action taken under the MDA, for
example invoking importation controls using the General
Importation Licensing provisions and encouraging local council
trading standards staff to take action against ‘head shops’ selling
‘legal highs’. This approach, which envisages use of existing
powers, is taken further in recent Irish legislation aimed at
regulating ‘head shops’ (the Criminal Justice (Psychoactive
Substances) Act 2010) as mentioned in chapter 2.
The use of controls across a particular drug and its
analogues (a whole group of very similar substances) is another
tactic adopted within the existing framework. This happened
with anabolic steroids and with cathinones. However, as raised in
chapter 2, a generic approach needs to be weighed against the
possible downside of potentially discouraging the research and
development of drugs with possible beneficial medical impacts.
Reclassifying and rescheduling are also appropriate and
legitimate responses, though many observers would comment
that the traumatic experience of the reclassification of cannabis
does not auger well for those who argue for less punitive
sanctions for cannabis possession or growing for personal use.
Indeed, it could be argued that all these options have already
been tried without huge success in limiting use but certainly
impacting on police and courts’ time.
Parliament could go further and amend the sentences for
possession offences under the MDA in order to remove the threat
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of imprisonment (depenalisation) or it could even remove
criminal sanctions altogether for simple possession offences and
instead put in place a series of civil penalties (possession
decriminalisation). This is the approach adopted by Portugal,
discussed in chapter 2. All of these approaches have, at various
times, been proposed by a number of bodies. Recently, for the
first time, the Advisory Council on the Misuse of Drugs (ACMD)
has raised the idea of decriminalising personal possession for all
drugs.139
All these options are valid within the parameters and spirit
of the international conventions, but such tinkering with the
system has led to an accretion of control measures. While they
may be pragmatic responses to changing circumstances, there is
the danger that they simply lead to further inconsistencies and
confusion. Moreover, these ad hoc changes are unlikely to satisfy
advocates on either side of the drug debate spectrum: those who
argue for more fundamental change on the one hand, and those
who favour an uncompromising stand against drugs on the
other. What muddies the water is that in the public mind drug
use is seen as synonymous with crime, especially when it comes
to an addiction driving acquisitive crime. This takes us to the
fourth option for change, which begins to see drug use and the
use of new substances as a significant public health challenge.
Figure 3 illustrates how governments control potentially harmful
substances.
Option 4 Control through consumer protection legislation or
regulations
Our fourth option for addressing the growing challenge of new
‘legal highs’ is to turn towards controlling their production,
supply and use not through the MDA framework but rather
through consumer protection legislation, such as that enforced
through the local trading standards system. Trading Standards
officers have responsibility for overseeing an extensive range of
regulatory powers, including those relating to medicines,
poisons, agricultural chemicals, veterinary drugs, foodstuffs,
animal health, tobacco, alcohol, industrial chemicals and
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cosmetic products as well as health and safety. The law regula-
ting such substances, many of which are harmful or dangerous, is
extensive and complex. Trading Standards officers work closely
and in collaboration with the police and a wide range of other
bodies such as the Medicines and Healthcare Products Regulatory
Agency and Royal Mail to enforce controls and regulations on
the production, supply and use of those substances.
One such piece of legislation is the Intoxicating Substances
(Supply) Act 1985. This act came into being following the deaths
of many young people around the UK from the inhaling of
solvents, including glue. Even now, there are approximately 36
deaths each year related to volatile substances.140 The legislation
introduced stricter controls on the retailing of volatile
substances, most of which (gas, aerosols, glues and other
solvents) had approved or licensed commercial applications.
Manufacturers over the years have adapted their products to
make them less hazardous and retailers and wholesalers have
acted more responsibly in reducing access, especially to children
and young people.
This legislation could offer a vehicle to control the selling
of new unlicensed or unapproved substances such as ‘legal
highs’, either through physical outlets such as ‘head shops’ or
through internet sales. The UK Drug Policy Commission has
previously called for a new system outside the MDA of
temporarily controlling or regulating new drugs so that a full
assessment of their actual or potential harms can be
undertaken.141 It would be feasible to ensure that an amended
Intoxicating Substances (Supply) Act included provisions for the
use of temporary powers both to restrict sales and supply of
‘legal highs’ and to put the onus on suppliers and manufacturers
to demonstrate that their products were safe to use. In the event
that an assessment of harms did not confirm a satisfactory level
of proportionate safety, the legislation could provide for
restrictive control measures to be put in place, with either civil or
criminal penalties for breach.
Through taking such domestic legislative steps, the UK
would be adhering to the international drug control treaties
through means other than the MDA. The Coalition Government
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plans to set up new local authority led health and wellbeing
boards in England and this would provide a unique opportunity
to shape control of emerging ‘legal highs’ within this new public
health system. Such a step would not be without practical and
financial implications for local councils and trading standards
departments. We have not sought at this point to estimate any
financial implications but rather believe the general principle is
one worth exploring. By focusing on just new psychoactive
substances, it would also allow policy makers to evaluate the
impacts of complementary control regimes without reopening
the debate about whether to be ‘soft or hard’ on drugs.
In the second workshop, participants considered the make-
up of an ‘ideal’ regulatory system for new psychoactive
substances, which they considered would overall reduce harms.
Their control framework included licensed sellers with the
responsibility for providing labelling of harms and adverse
effects, product assurances and liability, and age restrictions. All
these are adopted in various forms with other potentially harmful
substances controlled through trading standards and consumer
protection regulatory legislation.
Option 5 A new Harmful Substances Control Act
The fifth option involves the creation of new more embracing
drug control legislation.142 This would consolidate a wide range
of existing legislative provisions covering controlled drugs with
at least those for the control of alcohol and tobacco.
A proposal for a Misuse of Substances Act was set out by a
Royal Society of Arts Commission on illegal drugs, communities
and public policy in their report Drugs – Facing Facts in 2007.
The RSA Commission concluded,
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the law as it stands embodies a classification of illegal drugs that is crude,
ineffective, riddled with anomalies and open to political manipulation... the
Misuse of Drugs Act 1971 and the subsequent legislation associated with it be
repealed and be replaced by a comprehensive Misuse of Substances Act.143
The commission proposed that the focus of the law should
not be on individual drugs (as in the existing MDA ABC
classification) but on the harms that drugs cause. At the heart of
a new framework should be an index of substance-related harms:
‘The index should be based on the best available evidence and
should be able to be modified in the light of new evidence – and
also in the light of the coming onto the market of new
substances.’
Others, including participants in the second workshop
conducted as part of this project, have raised the possibility of
integrating controls on a much wider range of chemicals and
harmful substances (eg medicines, solvents or poisons) into a
single Harmful Substances Control framework. The argument in
support of this approach is that ‘while it is traditional to regard
the other substances in isolated groups, they all overlap to a
greater or lesser extent’.144 It would also have the advantage of
decluttering the current drug control legislation and provide an
opportunity to remove a number of anomalies that have grown
up over the years. As suggested above, the launch of the new
body Public Health England could provide a unique
opportunity to progress fresh approaches to influence and
control potentially harmful behaviours.
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6 Conclusions and
recommendations
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The Misuse of Drugs Act (MDA) is 40 years old. The world we
face now, with emerging new psychoactive substances available
via the internet, is very different from what it was in 1971. The
vast number of drugs now controlled within it, the ever-
expanding range of new psychoactive substances, new routes of
supply and changing patterns of drug use make enforcement
increasingly difficult, if not impossible in many cases. Although
there is clearly still an important role for enforcement in
protecting public health and public safety, the enormity of the
challenge faced by enforcement agencies, and the drawbacks of
an enforcement-based approach, point to a need to review the
Coalition Government’s current approach to drug control to
determine whether the existing framework is fit for purpose in
the twenty-first century.
New psychoactive substances are quickly emerging, made
widely available over the internet, and their harms are unknown
and untested. This presents a serious concern for public health,
and requires a responsible government to confront this
challenge. The Coalition Government has proposed the
introduction of temporary bans on new psychoactive substances
under the MDA. However, there are a number of concerns about
this approach. A temporary ban is seen as potentially
undermining evidence-based policy making, is likely to be very
difficult if not impossible to enforce, may lead to the use of even
more harmful substances, and could potentially restrict the
development of substances with potential medical benefit. As a
simple extension of the current approach, it reinforces the tacit
belief that classifying a substance through the MDA will
inevitably prevent and deter manufacture, supply and use.
There is no solution or single best drug control option. To
claim there is requires either appealing to a set of values or an
ideology that others may disagree with, or the ability to conduct
a rigorous cost benefit analysis (which would still entail
underlying value judgements). A similar conclusion was reached
in a major review of evidence-based policy making by an
international team of scientists from a variety of fields.145
Nonetheless, the current system is unbalanced, being
weighted towards regulating new substances on the basis of a
precautionary principle, without addressing the problem of
enforceability or recognising the potential or unintended harms
that may result from this type of approach.
One reason for the failure to recognise this inherent bias
and to make improvements to drug policy is the entrenched,
polarised nature of the debate. As our project demonstrates,
there are ways in which the issue can be approached which
allows analysis of different options and the identification of
improvements to the current policy framework.
It is important for researchers and policy makers to
question the belief among the media and others that control and
prohibition invariably minimises harm, and consider the
implications of other complementary regulatory options for new
substances. We can also take account of the current political and
economic situation in Britain, and likely developments in the
near future, and think about how we can offer improvements to
policy in the current context that are in line with the
Government’s values and priorities.
Too often recommendations about drug policy reform are
idealistic and overly ambitious, ignoring realpolitik. They lack
sufficient sensitivity to the political realities that currently prevail.
Our approach in this report is pragmatic. Our recommendations
are based on three broad principles.
First, our project showed that it was possible to bring
together people from different sides of the debate to agree on a
range of actions that could improve the current situation. By first
agreeing on universally valuable outcomes, it was possible to
identify steps towards improving the current approach to the
problem of psychoactive substances. Although it does not seek to
provide a blueprint for all aspects of drug policy, our approach
presents a possible model for making decisions about drug
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policy that could prove fruitful for those developing policy
options for the future.
Second, we must address the imbalance in decision making
that leads to a bias in favour of the precautionary principle. This
includes, but is not limited to, giving greater attention to other
control mechanisms. It also includes recognising harms of some
enforcement as well as the benefits of taking some drugs – and
being able to talk about these openly and initiate research into
methodologies that permit investigation of these issues.
Third, there has been insufficient attention to a wide range
of other control mechanisms that have been used in the past for
other psychoactive substances; it would be worth exploring these
and evaluating the different outcomes. This includes potential
long-term reform to provide a comprehensive framework for
dealing with all psychoactive substances.
Focus on achieving outcomes where there is
consensus
Discussions around the Coalition Government’s legislative
response are necessary, but can lead to people taking up
intractable and entrenched positions that inhibit progress. By
focusing on outcomes that people from all sides of the debate
agree are important it is possible to move away from areas of
high contention and identify possible practical improvements.
For example, using the outcome of protecting young people as
the starting point, all participants in the first workshop were able
to agree on the importance of gathering information on new
substances for all stakeholders.
The following recommended areas for action were identified:
There should be continued investment and support for
broader intervention initiatives, delivered in schools and
communities, as well as family-based initiatives and
mentoring schemes in order to increase resilience to
problematic drug use.
These programmes aim to build broader networks of support for
young people at greater risk of ‘drug problems’. They also help
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to develop better emotional and social resilience enabling young
people to withstand the lure of drug use, or to experiment with
drugs without letting it diminish their ability to reach their
potential. The 2010 government drug strategy commendably
highlights the importance and role of broader support to reduce
the demand for drugs.146 This broader focus has a developing
evidence base and is something that stakeholders across the
spectrum of debate can agree on. The Government should
continue to invest in early intervention initiatives, such as Sure
Start and Family Nurse Partnerships and continue to build the
evidence base for such programmes. The Government has
pledged that the Early Intervention Grant and the Public Health
Grant will provide local authorities with the funding and
flexibility to tailor approaches to supporting vulnerable families.
The Government and local authorities must ensure that this
funding is spared from further spending cuts.
Government, local authorities and schools must ensure that
drug education is based on accurate information delivered
by individuals who will be perceived as credible and
authoritative.
The 2010 government drug strategy also recognises the
importance of providing accurate and reliable drug education
and information in schools and through the drugs advisory
service FRANK.147 The strategy advocates providing resources to
schools based on best practice, while giving them the freedom to
determine the approach they think is best. The experts involved
in our project indicated that schools must avoid only providing
scare-mongering messages to young people about the effects of
drugs. While the bleak realities of drug use should certainly be
conveyed to young people, they must be balanced by some
recognition of the perceived benefits of drug use. The most
effective messengers are likely to include other young people,
and people from the local area that young people can identify
with. The participants in our workshops also felt that it is
important to ensure there are alternative positive activities for
young people, such as team sports.
Conclusions and recommendations
A systematic framework for information collection should
be created to tap into the experience of users and frontline
workers, as an early warning system and a source of
knowledge about potential harms and perceived benefits
of new drugs.
The Coalition Government has announced the creation of ‘an
effective forensic early warning system’ as part of its efforts to
tackle new psychoactive substances, but the details of how such a
system would function are unknown. Nor is it clear how the
Government will make use of similar initiatives, for example, the
Europe-wide Psychonaut Web Mapping Project based at King’s
College. This searches the internet and user forums and supplier
websites to analyse new and emerging substances, and some of
the perceived effects of substances. While there are clear
drawbacks to user based reports – for example, experts cannot
be sure that drugs actually contain the substances they advertise
– this type of initiative can help to provide real-time information
into European drug markets. The Government should recognise
that when a substance is banned even temporarily, it becomes
increasingly difficult to gather accurate information on the effects
of new substances on users. A more effective, evidence-based
approach could be pursued using early warning monitoring and
information gathering, and regulation through consumer
protection channels outside the MDA. This form of regulation
could then be supplemented by a framework for sharing
information among pharmacologists, frontline charities and
users to gather and disseminate information on harmful effects.
The development and evaluation of outreach approaches,
such as use of amnesty bins in clubs and other venues
where use of such drugs is prevalent, should be increased
to enable people to adopt less risky behaviours if they do
decide to use, but also to provide valuable information
about the availability and purity of new substances.
Research over the past 20 years into prevalence of drug use in
the UK shows that despite significant investment in tackling
illicit substances, millions of people continue to gain access to
and use them. Moreover, illicit substances controlled through the
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MDA are almost inevitably and increasingly cut with other licit
and illicit substances that pose harms in themselves and increase
the risk of people taking dangerous-sized doses. The Govern-
ment and enforcement agencies should continue to support
pragmatic approaches to personal possession and drug use in an
effort to reduce harm. For new psychoactive substances – most
of which include pills – such approaches would include measures
such as pill testing facilities and amnesty bins in clubs, festivals
and other venues where drug taking is prevalent although their
impact needs to be evaluated. A number of frontline charities,
including Crew 2000 in Scotland, already provide a number of
outreach services in nightclubs and festivals. Government
support for charities like Crew 2000 doing outreach, as well as
the use of amnesty bins and drug testing, should continue in
order to facilitate the gathering of information of pattern of drug
use and the chemical content of new drugs.
The Government should invest in laboratory-based
investigation of current and potential drugs of abuse.
Laboratory-based investigations can provide some indication of
the likely effects of new substances after they have been detected,
or even before this. This may help policy makers in deciding
what types of regulation might be most appropriate and what
effects to look out for. This might be an area where co-ordination
and co-operation within the EU would be an efficient way of
maximising use of resources.
Ensure a more balanced decision-making process and
debate
As discussed in chapter 2, the conclusion of Peter Reuter’s paper
is that there is a fundamental bias in the political and regulatory
system towards prohibition of new psychoactive substances:
Conclusions and recommendations
The adverse consequences of mistakenly refraining from prohibiting what
may turn out to be a dangerous drug are massive both for the individual
decision maker and for the political party in power at the time. On the other
hand the gains from correctly allowing a new psychoactive substance enter
into the market, with appropriate regulatory controls, are modest and not
very salient for the decision maker or the government. A Type II error
(allowing what should have been prohibited) has much greater consequences
than avoiding a Type I error (prohibiting what should have been allowed).
That will be true even with a broader array of legal options. Once the
decision not to prohibit is explicit, the decision maker faces a risk of
significant public retribution.148
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There are a number of parallels here with the challenges
facing regulatory agencies when deciding whether to bring a
therapeutic medicine to market.149 Regulatory agencies have to
balance the risk of taking a medicine to market too quickly to
provide the benefit to individual users, with the cautious
tendency to withhold it until there is greater assurance of low
harms. When considering whether to bring therapeutic
medicines to market, the benefits to individual users are a
significant part of the decision. The benefits to individual users
of new psychoactive substances are different and some would
argue less morally relevant.
There is an argument that new substances can provide a
safer substitute for other more harmful substances. As discussed
above, there is some evidence to suggest this was the case with
mephedrone and cocaine. However, because the long-term effects
of new substances may take some time to become apparent,
making a judgement about whether or not they are in fact safer
overall is essentially a gamble. There are also the harms related to
prohibition to be considered. These include: eliminating the
possibility of providing quality control and assurance; increasing
the potential harms to individual users; complicating the task of
gathering data on the substance that would allow for a more
informed decision, since there are no manufacturers with an
incentive to collect and analyse such data; and making it less
likely that respondents in studies will disclose use.150
As Reuter argues, it is thus important to develop ways to
‘override this bias and to ensure a more balanced set of regulatory
decisions’, which requires, in part, a shift in public opinion to
consider the benefits of drug taking, including the potential for
less harmful drugs to substitute for more harmful drugs.151
As a result, we make the following recommendations:
The Government should conduct more rigorous research
into the full range of impacts (including unintended harms)
of the control and enforcement elements of drug control
and drug policy.
The Government needs to improve the quality of impact
assessments on drug harms and the harms of different drug
policy options, despite the methodological challenges this
throws up. The harms from drug use require data on the
numbers of users, hospital admissions, deaths and dependent
users. It would also be helpful to have data on the numbers of
admissions and deaths caused or aggravated by impurities in the
drugs used and the number of incidents involving multiple drug
use. There are harms from drug control itself that also require
documentation and data, including the number of people with
drug cautions and drug convictions. These are critical data for
the construction of effective drug policies.
The Government should give greater consideration to
identifying and assessing the benefits (in addition to the
harms) that individuals and society may derive from using
psychoactive substances, including the potential for
substitution for more harmful substances.
Government legislation and pronouncements recognise the
benefits (beyond medicinal) of using alcohol, which factors into
their analysis, but fail to do so with other recreational drugs. As
mentioned in chapter 2, the 2010 drug strategy acknowledges the
contribution of alcohol to ‘community and family life’, as well as
the ‘cultural life of this country’ in addition to the ‘valuable
revenue it generates to the economy’ as a result of the manner in
which alcohol is regulated. While the authors are not arguing
that the benefit of pleasure to users should be on par with
potential medical benefits of substances, they ought to be taken
into account for the sake of consistency. Therefore surveys
relating to drug use should find out the reasons why some young
people take drugs and some do not. There is also the potential
benefit that a new psychoactive substance may be functioning as
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a safer substitute to more harmful drugs but to assess this will
require study and an evaluation of a functioning and active
market. Gathering this type of information is easier within a
regulated market – for example, along the lines of the New
Zealand ‘restricted substances’ – than after prohibition.
Consider other regulatory options for control
We believe there is now a need to consider a shift to the policy
debate to focus on the wide range of regulatory options
available, not just the MDA. This can potentially allow improve-
ments to policy without having to become entrenched in the
legalise versus criminalise debate. It could encourage a broader
consideration of the impact of complementary legislative options,
for example regulation through the MDA, versus consumer
protection perhaps through the Intoxicating Substances
(Supply) Act giving a focus entirely on supply control.
We therefore make the following recommendations.
In the short term the Government should commit to a
comprehensive assessment of the use and impact of
planned temporary banning powers.
Our project revealed significant concerns among experts that the
temporary ban could be unenforceable, lead to other harms, and
lead to a neglect in considering other options. The Government
needs to confront the increasing unenforceability of the MDA in
light of the rapid growth in the synthetic drugs market.
In the short term the Government should give greater
consideration to controlling the supply of new
psychoactive drugs through the wide range of consumer
protection legislation in some instances.
Trading Standards officers and the Medicines and Healthcare
Products Regulatory Agency oversee a wide range of regulatory
powers, some of which could be applied to new ‘legal highs’,
such as the Intoxicating Substances (Supply) Act 1985. This
control framework would or could require such things as
licensed suppliers, proper labelling of harms and adverse effects,
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product assurances and liability, age restrictions and appropriate
sanctions, whether criminal or civil for breaches. Such measures
would comply with international obligations, provide a
proportionate response to the challenge and avoid some (but not
all) of the consequences of any control regime. It would also
allow a full evaluation to be made of the contrasting approaches
to control in order to inform future drug policy.
In the long term the Government should consider a radical
reform of the measures for the control of psychoactive
substances to provide an overall and integrated framework
for controlling the supply of all psychoactive substances,
including alcohol, tobacco and solvents.
A new Harmful Substances Control Act or framework could be
developed. This is an extension of the idea that has been
recommended by the RSA Drug Policy Commission and by Dr
Les King, a well-known pharmacologist, forensic scientist and
former member of the Advisory Council on the Misuse of Drugs
(ACMD). Essentially, this would consolidate a wide range of
existing legislative provisions covering controlled drugs with
those at least for alcohol and tobacco and even perhaps those
covering the control of medicines and poisons. This has the
advantage of de-cluttering the current drug control legislation
and providing an opportunity to remove anomalies that have
grown up over the years.
One of the biggest criticisms of current policy is that
harmful substances are dealt with through a range of legislative
frameworks. For example, solvents are regulated through the
Intoxicating Substances Act; alcohol and tobacco are regulated
through Trading Standards and licensing; while cannabis is
classified according to the MDA. This is not only inefficient; it
sends confusing messages about the potential harms of such
substances, especially to young people who have access to a
plethora of information routes. The Government will find it hard
to continue to ignore many of the perceived contradictions
inherent in its various approaches to harmful substances. It
should commit to undertaking a review to consider the
implications of consolidating all legislation that covers
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potentially harmful substances, including alcohol and tobacco,
into one Harmful Substances Control Act.
In summary, it is 40 years since the Misuse of Drugs Act
1971 became law and the ‘drug problem’ is no nearer being
solved. The new psychoactive substances now being developed
pose new challenges while at the same time our understanding of
the problems associated with licit substances has grown.
Therefore it seems high time for a new approach. The drugs
debate is a hotly contested and polarised area and anyone
entering it runs the risk of being characterised as being on one
side or the other. However, it is clear that the ‘drug problem’ is
complex and multi-faceted and there is no simple solution to it.
We would suggest that it is time for a new approach to policy
making, legislation and debate on drugs issues focusing on
developing consensus and taking a more holistic view of
substance use while building better evidence about what works.
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Glossary of key drug policy terms
There is often confusion about the terminology concerning
approaches to the control psychoactive substances. The
following list provides clarification of the meaning of key terms
used in this report.
Control The term ‘control’ encompasses the full
array of legislative approaches for
restricting the availability of various sub-
stances. It includes laws such as the Misuse
of Drugs Act, which make some substances
illegal to use / possess / sell, as well as
regulations concerned with the manu-
facturing, dispensing, approval and
marketing of substances that have medical
or commercial uses, or are seen as ‘accept-
able’, such as alcohol, solvents, inhalants
etc. Thus, Government ‘controls’ cannabis,
for example, through the Misuse of Drugs
Act, and ‘controls’ tobacco through Trading
Standards regulations. The level of control
varies according to the mechanism. The
Misuse of Drugs Act controls substances
through enforcement with the threat of
criminal penalties, while Trading Standards
controls the selling of food, most often
through civil penalties and fines. 
Decriminalisation ‘Decriminalisation’ refers to the repeal of
laws that define drug use or possession (but
not selling or distribution) as criminal
offences. It does this through either total
repeal of penal punishments (ie prison
sentences) or shifting the basis to civil
penalties, such as fines or removal of a
licence, or administrative processes, eg in
Portugal. In Portugal, drug use and
possession are still legally prohibited, but
violations are deemed to be simply
administrative offences and are dealt with
by ‘Commissions for Dissuasions of Drug
Addiction’ rather than criminal courts.
Depenalisation ‘Depenalisation’ refers to the reduction of
the level of penalties associated with drug
offences, usually those for personal use or
possession. For example, ‘depenalisation’
applies to the introduction of warnings or
cautions for cannabis possession, rather
than potential time in prison.
Legalisation ‘Legislation’ refers to making drug use,
possession, production and distribution
legal. Unlike decriminalisation, legalisation
would repeal all penalties, criminal and
civil, for use, possession, production and
distribution of a substance. However,
‘legalisation’ would most likely still require
other types of controls and regulations put
in place (e.g. restrictions to licensed
proprietors, and age restrictions on sales).
Regulation ‘Regulation’ (both domestic and
international) imposes conditions on the
manufacturing, dispensing, approval and
marketing of substances. These laws bind
manufacturers and distributors and
penalties range in severity and may be civil
or criminal. Examples include food
labelling requirements, age restrictions on
sales, and the more stringent controls for
dispensing medicines.
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Workshop questionnaires
Please indicate the extent to which you agree or disagree with the
following statements on a scale from 1 (strongly agree) to 5
(strongly disagree) by circling the relevant number.
Strongly Slightly Neither Slightly Strongly 
agree agree agree or disagree disagree
disagree
1 It is important that the 1 2 3 4 5
Government classifies 
new psychoactive 
substances as quickly 
as possible.
2 Classifying drugs under 1 2 3 4 5
the Misuse of Drugs Act 
is the most effective 
approach to protect 
young people from 
harmful substances.
3 The Misuse of Drugs 1 2 3 4 5
Act and the current 
classification system 
act as an effective 
deterrent to use 
among young people.
4 The Government’s 1 2 3 4 5
proposal for a temporary 
ban on new emerging 
substances will be the 
most effective approach 
to protect young people 
from the harm of new 
emerging psychoactive 
substances.
5 I think I understand 1 2 3 4 5
young people’s 
motivations for using 
new emerging synthetic 
substances.
6 Providing drug 1 2 3 4 5
education/information 
to young people is an 
effective deterrent to 
use.
7 The phenomenon of 1 2 3 4 5
new emerging synthetic 
substances requires a 
completely new 
approach to drug 
control.
Post-workshop questionnaire
Please indicate the extent to which you agree or disagree with the
following statements on a scale from 1 (strongly agree) to 5
(strongly disagree) by circling the relevant number.
Strongly Slightly Neither Slightly Strongly 
agree agree agree or disagree disagree
disagree
1 It is important that the 1 2 3 4 5
Government classifies 
new psychoactive 
substances as quickly 
as possible.
2 Classifying drugs under 1 2 3 4 5
the Misuse of Drugs Act 
is the most effective 
approach to protect 
young people from 
harmful substances.
3 The Misuse of Drugs 1 2 3 4 5
Act and the current 
classification system 
act as an effective 
deterrent to use 
among young people.
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4 The Government’s 1 2 3 4 5
proposal for a 
temporary ban on new 
emerging substances 
will be the most 
effective approach to 
protect young people 
from the harm of new 
emerging psychoactive 
substances.
5 I think I understand 1 2 3 4 5
young people’s 
motivations for using 
new emerging synthetic 
substances.
6 Providing drug 1 2 3 4 5
education/information 
to young people is an 
effective deterrent to 
use.
7 The phenomenon of 1 2 3 4 5
new emerging synthetic 
substances requires a 
completely new approach 
to drug control.
8 Has your view on drug issues and how to best protect young people
changed in any way as a result of participating in the workshop? If possible
please indicate below or on the reverse of this page the main change that
has occurred for you.
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exercise of the rights granted here under. You may not sublicence the Work. You must keep
intact all notices that refer to this Licence and to the disclaimer of warranties. You may not
distribute, publicly display, publicly perform, or publicly digitally perform the Work with any
technological measures that control access or use of the Work in a manner inconsistent with
the terms of this Licence Agreement. The above applies to the Work as incorporated in a
Collective Work, but this does not require the Collective Work apart from the Work itself to
be made subject to the terms of this Licence. If You create a Collective Work, upon notice
from any Licensor You must, to the extent practicable, remove from the Collective Work any
reference to such Licensor or the Original Author, as requested.
B You may not exercise any of the rights granted to You in Section 3 above in any manner that
is primarily intended for or directed towards commercial advantage or private monetary
Licence to Publish
compensation. The exchange of the Work for other copyrighted works by means of digital
filesharing or otherwise shall not be considered to be intended for or directed towards
commercial advantage or private monetary compensation, provided there is no payment of
any monetary compensation in connection with the exchange of copyrighted works.
C If you distribute, publicly display, publicly perform, or publicly digitally perform the Work or
any Collective Works, You must keep intact all copyright notices for the Work and give the
Original Author credit reasonable to the medium or means You are utilising by conveying the
name (or pseudonym if applicable) of the Original Author if supplied; the title of the Work if
supplied. Such credit may be implemented in any reasonable manner; provided, however, that
in the case of a Collective Work, at a minimum such credit will appear where any other
comparable authorship credit appears and in a manner at least as prominent as such other
comparable authorship credit.
5 Representations, Warranties and Disclaimer
A By offering the Work for public release under this Licence, Licensor represents and warrants
that, to the best of Licensor’s knowledge after reasonable inquiry:
i Licensor has secured all rights in the Work necessary to grant the licence rights hereunder
and to permit the lawful exercise of the rights granted hereunder without You having any
obligation to pay any royalties, compulsory licence fees, residuals or any other payments;
ii The Work does not infringe the copyright, trademark, publicity rights, common law rights or
any other right of any third party or constitute defamation, invasion of privacy or other
tortious injury to any third party.
B except as expressly stated in this licence or otherwise agreed in writing or required by
applicable law, the work is licenced on an ‘as is’ basis, without warranties of any kind, either
express or implied including, without limitation, any warranties regarding the contents or
accuracy of the work.
6 Limitation on Liability
Except to the extent required by applicable law, and except for damages arising from liability
to a third party resulting from breach of the warranties in section 5, in no event will Licensor
be liable to you on any legal theory for any special, incidental, consequential, punitive or
exemplary damages arising out of this licence or the use of the work, even if Licensor has
been advised of the possibility of such damages.
7 Termination
A This Licence and the rights granted hereunder will terminate automatically upon any breach
by You of the terms of this Licence. Individuals or entities who have received Collective
Works from You under this Licence, however, will not have their licences terminated provided
such individuals or entities remain in full compliance with those licences. Sections 1, 2, 5, 6, 7,
and 8 will survive any termination of this Licence.
B Subject to the above terms and conditions, the licence granted here is perpetual (for the
duration of the applicable copyright in the Work). Notwithstanding the above, Licensor
reserves the right to release the Work under different licence terms or to stop distributing the
Work at any time; provided, however that any such election will not serve to withdraw this
Licence (or any other licence that has been, or is required to be, granted under the terms of
this Licence), and this Licence will continue in full force and effect unless terminated as stated
above.
8 Miscellaneous
A Each time You distribute or publicly digitally perform the Work or a Collective Work, Demos
offers to the recipient a licence to the Work on the same terms and conditions as the licence
granted to You under this Licence.
B If any provision of this Licence is invalid or unenforceable under applicable law, it shall not
affect the validity or enforceability of the remainder of the terms of this Licence, and without
further action by the parties to this agreement, such provision shall be reformed to the
minimum extent necessary to make such provision valid and enforceable.
C No term or provision of this Licence shall be deemed waived and no breach consented to
unless such waiver or consent shall be in writing and signed by the party to be charged with
such waiver or consent.
D This Licence constitutes the entire agreement between the parties with respect to the Work
licenced here. There are no understandings, agreements or representations with respect to
the Work not specified here. Licensor shall not be bound by any additional provisions that
may appear in any communication from You. This Licence may not be modified without the
mutual written agreement of Demos and You.
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The proliferation of new psychoactive substances, or
‘legal highs’, has caused moral panic in recent years.
But it has also thrown the existing regulatory measures
for drugs into sharp relief. As quickly as policy makers
to seek to control new substances through the Misuse
of Drugs Act, others are being manufactured and put
on the market. The effects of these new substances are
unknown and untested and it is this uncertainty
combined with easy accessibility that presents major
challenges to public safety.
However, these challenges also provide an
opportunity to look again at drug control policy
without a rerun of redundant debates about whether
to be ‘tough’ or ‘soft’ on drugs. Instead, this pamphlet
adopts a systems approach and considers drug policy
as a ‘wicked issue’ to which there is no solution, and no
ultimate winners or losers. Fundamentally, it seeks an
improvement to policy that will be supported by
people who otherwise disagree about what the goals
of policy are.
It is 40 years since the Misuse of Drugs Act
became law and the ‘drug problem’ is no nearer being
solved. Taking Drugs Seriously argues that it is time for
a new approach to policy making, legislation and
debate on drugs issues, focusing on developing
consensus while building better evidence about what
works.
Jonathan Birdwell is a Researcher at Demos. Jake
Chapman is an Associate of Demos. Nicola Singleton is
Director of Policy and Research at the UK Drug Policy
Commission.
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